<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="ebs" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">ebs</book-part-id>
      <title-group>
        <title>Epidermolysis Bullosa Simplex</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pfendner</surname>
            <given-names>Ellen G</given-names>
          </name>
          <degrees>PhD</degrees>
          <aff>GeneDx, Inc<break/>Gaithersburg, Maryland</aff>
          <email>ellen@genedx.com</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bruckner</surname>
            <given-names>Anna L</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Department of Dermatology<break/>University of Colorado School of Medicine<break/>Aurora, Colorado</aff>
          <email>anna.bruckner@ucdenver.edu</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>7</day>
          <month>10</month>
          <year>1998</year>
        </date>
        <date date-type="updated">
          <day>13</day>
          <month>10</month>
          <year>2016</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="msx2" document-type="chapter">Enlarged Parietal Foramina</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="eb-pa" document-type="chapter">Epidermolysis Bullosa with Pyloric Atresia</related-object>
      <abstract id="ebs.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Epidermolysis bullosa simplex (EBS) is characterized by fragility of the skin (and mucosal epithelia in some cases) that results in non-scarring blisters and erosions caused by minor mechanical trauma. The current classification of epidermolysis bullosa (EB) includes two major types and 17 minor subtypes of EBS; all share the common feature of blistering above the dermal-epidermal junction at the ultrastructural level. The four most common subtypes of EBS are the focus of this <italic toggle="yes">GeneReview</italic>:</p>
          <list list-type="bullet">
            <list-item>
              <p>EBS, localized (EBS-loc; previously known as Weber-Cockayne type)</p>
            </list-item>
            <list-item>
              <p>EBS, generalized intermediate (EBS-gen intermed; previously known as Koebner type)</p>
            </list-item>
            <list-item>
              <p>EBS-with mottled pigmentation (EBS-MP)</p>
            </list-item>
            <list-item>
              <p>EBS, generalized severe (EBS-gen sev; previously known as Dowling-Meara type)</p>
            </list-item>
          </list>
          <p>The phenotypes for these subtypes range from relatively mild blistering of the hands and feet to more generalized blistering, which can be fatal.</p>
          <list list-type="bullet">
            <list-item>
              <p>In EBS-loc, blisters are rarely present or minimal at birth and may occur on the knees and shins with crawling or on the feet at approximately age 18 months; some individuals manifest the disease in adolescence or early adulthood. Blisters are usually confined to the hands and feet, but can occur anywhere if trauma is significant.</p>
            </list-item>
            <list-item>
              <p>In EBS, gen intermed, blisters may be present at birth or develop within the first few months of life. Involvement is more widespread than in EBS-loc, but generally milder than in EBS-gen sev.</p>
            </list-item>
            <list-item>
              <p>In EBS-MP, skin fragility is evident at birth and clinically indistinguishable from EBS-gen sev; over time, progressive brown pigmentation interspersed with hypopigmented spots develops on the trunk and extremities, with the pigmentation disappearing in adult life. Focal palmar and plantar hyperkeratoses may occur.</p>
            </list-item>
            <list-item>
              <p>In EBS-gen sev, onset is usually at birth; severity varies greatly, both among and within families. Widespread and severe blistering and/or multiple grouped clumps of small blisters are typical and hemorrhagic blisters are common. Improvement occurs during mid- to late childhood. Progressive hyperkeratosis of the palms and soles begins in childhood and may be the major complaint of affected individuals in adult life. Nail dystrophy and milia are common. Both hyper- and hypopigmentation can occur. Mucosal involvement in EBS-gen sev may interfere with feeding, especially in neonates and infants. Blistering can be severe enough to result in neonatal or infant death.</p>
            </list-item>
          </list>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of epidermolysis bullosa simplex (EBS) is established in a proband by the identification of biallelic pathogenic variants in <italic toggle="yes">EXPH5</italic> or <italic toggle="yes">TGM5</italic> or heterozygous (or rarely biallelic) pathogenic variants in <italic toggle="yes">KRT5</italic> or <italic toggle="yes">KRT14</italic> by molecular genetic testing; examination of a skin biopsy using immunofluorescence microscopy and transmission electron microscopy may be considered but can have limitations in the diagnosis of EBS.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Supportive care to protect the skin from blistering; use of dressings that will not further damage the skin and will promote healing of open wounds. Lance and drain new blisters. Dressings involve three layers: a primary nonadherent contact layer; a secondary layer providing stability, adding padding, and absorbing drainage; and a tertiary layer with elastic properties.</p>
          <p><italic toggle="yes">Prevention of primary manifestations:</italic> Aluminum chloride (20%) applied to palms and soles can reduce blister formation in some individuals with EBS. Cyproheptadine (Periactin<sup>&#x000ae;</sup>), tetracycline, erythromycin, or botulimun toxin can reduce blistering in some individuals. Keratolytics and softening agents for palmar plantar hyperkeratosis may prevent tissue thickening and cracking.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Monitor for wound infection; treatment with topical and/or systemic antibiotics or silver-impregnated dressings or gels can be helpful. Nutritional support and feeding therapy may be necessary for infants and children with oral manifestations of EBS. Management of fluid and electrolyte problems in severely affected infants. Appropriate footwear and physical therapy may preserve ambulation in children who have difficulty walking because of blistering and hyperkeratosis.</p>
          <p><italic toggle="yes">Surveillance:</italic> For infection and proper wound healing.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Excessive heat may exacerbate blistering and infection. Avoid poorly fitting or coarse-textured clothing/footwear and activities that traumatize the skin. Avoid ordinary medical tape or Band-Aids<sup>&#x000ae;</sup>.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>EBS caused by pathogenic variants in <italic toggle="yes">EXPH5</italic> or <italic toggle="yes">TGM5</italic> is inherited in an autosomal recessive manner. EBS caused by pathogenic variants in <italic toggle="yes">KRT5</italic> or <italic toggle="yes">KRT14</italic> is usually inherited in an autosomal dominant manner, but in rare families (especially those with consanguinity) it can be inherited in an autosomal recessive manner.</p>
          <list list-type="bullet">
            <list-item>
              <p>In families with autosomal recessive inheritance, the parents of an affected child are obligate heterozygotes; at conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being heterozygous, and a 25% chance of being unaffected and not a heterozygote.</p>
            </list-item>
            <list-item>
              <p>In families with autosomal dominant inheritance, each child of an affected individual has a 50% chance of inheriting the pathogenic variant and having EBS.</p>
            </list-item>
          </list>
          <p>Molecular genetic testing for at-risk family members and prenatal testing for pregnancies at increased risk are possible if the pathogenic variant(s) in the family are known.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="ebs.GeneReview_Scope">
        <title><italic toggle="yes">GeneReview</italic> Scope</title>
        <table-wrap id="ebs.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_ebs.Tc_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Epidermolysis Bullosa Simplex: Included Phenotypes</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_ebs.Tc_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Epidermolysis bullosa simplex with mottled pigmentation (EBS-MP)</p></list-item><list-item><p>Epidermolysis bullosa simplex, generalized severe (EBS-gen sev)</p></list-item><list-item><p>Epidermolysis bullosa simplex, localized (EBS-loc)</p></list-item><list-item><p>Epidermolysis bullosa simplex, generalized intermediate (EBS-gen intermed)</p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>For synonyms and outdated names see <xref ref-type="sec" rid="ebs.Nomenclature">Nomenclature</xref>.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="ebs.Diagnosis">
        <title>Diagnosis</title>
        <sec id="ebs.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>The diagnosis of epidermolysis bullosa simplex (EBS) <bold>should be suspected</bold> in individuals with the following clinical findings:</p>
          <list list-type="bullet">
            <list-item>
              <p>Fragility of the skin manifested by blistering with little or no trauma, which typically heals without scarring</p>
            </list-item>
            <list-item>
              <p>Blistering that:</p>
              <list list-type="bullet">
                <list-item>
                  <p>May be present in the neonatal period</p>
                </list-item>
                <list-item>
                  <p>Primarily affects the hands and feet but can affect the whole body</p>
                </list-item>
                <list-item>
                  <p>Occurs in annular or curvilinear groups or clusters</p>
                </list-item>
                <list-item>
                  <p>Can lead to progressive brown pigmentation interspersed with hypopigmented spots on the trunk and extremities that frequently disappears in adult life</p>
                </list-item>
                <list-item>
                  <p>Is associated with palmar and plantar hyperkeratosis that may be severe</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Nail dystrophy</p>
            </list-item>
            <list-item>
              <p>Milia</p>
            </list-item>
            <list-item>
              <p>Family history that is consistent with either an autosomal recessive or autosomal dominant inheritance pattern</p>
              <p>Note: Absence of a known family history of EBS does not preclude the diagnosis.</p>
            </list-item>
          </list>
        </sec>
        <sec id="ebs.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of epidermolysis bullosa simplex (EBS) <bold>is best established</bold> in a proband by the identification of biallelic pathogenic variants in <italic toggle="yes">EXPH5</italic> or <italic toggle="yes">TGM5</italic> or heterozygous (or rarely biallelic) pathogenic variants in <italic toggle="yes">KRT5</italic> or <italic toggle="yes">KRT14</italic> by molecular genetic testing (see <xref ref-type="table" rid="ebs.T.molecular_genetic_testing_used_in">Table 1</xref>). Examination of a skin biopsy using immunofluorescence microscopy and transmission electron microscopy (see <bold>Skin biopsy</bold> below) may be considered but can have limitations in the diagnosis of EBS.</p>
          <p>Molecular testing approaches can include <bold>serial single-gene testing</bold>, use of a <bold>multi-gene panel</bold>, and <bold>more comprehensive genomic testing</bold>.</p>
          <p>
            <bold>Serial single-gene testing</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Sequence analysis of <italic toggle="yes">KRT5</italic> and <italic toggle="yes">KRT14</italic> is performed first.</p>
            </list-item>
            <list-item>
              <p>If no pathogenic variants are found in <italic toggle="yes">KRT5</italic> or <italic toggle="yes">KRT14</italic> by sequence analysis, sequence analysis of <italic toggle="yes">EXPH5</italic> and <italic toggle="yes">TGM5</italic> should be considered next.</p>
            </list-item>
            <list-item>
              <p>If sequence analysis of <italic toggle="yes">EXPH5</italic> and <italic toggle="yes">TGM5</italic> reveals no or only one pathogenic variant, gene-targeted deletion/duplication analysis of <italic toggle="yes">EXPH5</italic>, <italic toggle="yes">KRT5</italic>, <italic toggle="yes">KRT14</italic>, and/or <italic toggle="yes">TGM5</italic> may be considered. Note, however:</p>
              <list list-type="bullet">
                <list-item>
                  <p>The majority of pathogenic variants in <italic toggle="yes">KRT5</italic> and <italic toggle="yes">KRT14</italic> are dominant-negative missense variants inherited in an autosomal dominant manner.</p>
                </list-item>
                <list-item>
                  <p>Loss-of-function variants in <italic toggle="yes">EXPH5</italic>, <italic toggle="yes">KRT5</italic>, <italic toggle="yes">KRT14</italic>, and <italic toggle="yes">TGM5</italic> occur rarely and cause recessive disease.</p>
                </list-item>
                <list-item>
                  <p>No large deletion or duplication in <italic toggle="yes">EXPH5</italic>, <italic toggle="yes">KRT5</italic>, <italic toggle="yes">KRT14</italic>, or <italic toggle="yes">TGM5</italic> has been reported.</p>
                </list-item>
              </list>
              <p>Therefore, a multigene panel or genomic testing may be higher yield than deletion/duplication analysis.</p>
            </list-item>
          </list>
          <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">EXPH5</italic>, <italic toggle="yes">KRT5</italic>, <italic toggle="yes">KRT14</italic>, <italic toggle="yes">TGM5</italic> and other genes of interest (see <xref ref-type="sec" rid="ebs.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and over time. (2) Some multi-gene panels may include genes unrelated to the disorder of interest; thus, clinicians need to determine which multi-gene panel provides the best opportunity to identify the genetic cause of the condition at the most reasonable cost. (3) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.</p>
          <p>For more information on multi-gene panels click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.MultiGene_Panels" object-type="sec">here</related-object>.</p>
          <p><bold>More comprehensive genomic testing</bold> (when available) including exome sequencing and genome sequencing may be considered if serial single-gene testing (and/or use of a multi-gene panel that includes EXPH5, <italic toggle="yes">KRT5</italic>, <italic toggle="yes">KRT14</italic>, and <italic toggle="yes">TGM5</italic>) fails to confirm a diagnosis in an individual with features of EBS. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different gene or genes that results in a similar clinical presentation). For more information on comprehensive genome sequencing click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.Comprehensive_Genome_Sequencing" object-type="sec">here</related-object>.</p>
          <table-wrap id="ebs.T.molecular_genetic_testing_used_in" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Molecular Genetic Testing Used in Epidermolysis Bullosa Simplex (EBS)</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_2">Proportion of EBS Attributed to Pathogenic Variants in This Gene</th>
                  <th id="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> Detected by Test Method&#x000a0;<sup>3</sup></th>
                </tr>
                <tr>
                  <th headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">Sequence analysis&#x000a0;<sup>4</sup></th>
                  <th headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>5</sup></th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">EXPH5</italic>
                  </td>
                  <td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Estimated at 1%-2%</td>
                  <td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;90%</td>
                  <td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Unknown&#x000a0;<sup>6</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">KRT5</italic>
                  </td>
                  <td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">~37%&#x000a0;<sup>7</sup></td>
                  <td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">~99%&#x000a0;<sup>8,&#x000a0;9</sup></td>
                  <td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Unknown&#x000a0;<sup>6</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">KRT14</italic>
                  </td>
                  <td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">~37%&#x000a0;<sup>7</sup></td>
                  <td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">~99%&#x000a0;<sup>8,&#x000a0;10</sup></td>
                  <td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Unknown&#x000a0;<sup>6</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">TGM5</italic>
                  </td>
                  <td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Estimated at 5%</td>
                  <td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;90%&#x000a0;<sup>11</sup></td>
                  <td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Unknown&#x000a0;<sup>6</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Other or unknown&#x000a0;<sup>12</sup></td>
                  <td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">~19%</td>
                  <td headers="hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_2_1 hd_h_ebs.T.molecular_genetic_testing_used_in_1_1_2_2" valign="middle" colspan="2" align="left" rowspan="1">NA</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="ebs.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="ebs" object-id="ebs.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="ebs.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="ebs.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="ebs.TF.1.3">
                <label>3. </label>
                <p>In individuals with biopsy-diagnosed EBS</p>
              </fn>
              <fn id="ebs.TF.1.4">
                <label>4. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="ebs.TF.1.5">
                <label>5. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="ebs.TF.1.6">
                <label>6. </label>
                <p>No data on detection rate of gene-targeted deletion/duplication analysis are available. However, deletion/duplication analysis is likely to have a low yield for these genes (see <xref ref-type="sec" rid="ebs.Establishing_the_Diagnosis">Establishing the Diagnosis</xref>).</p>
              </fn>
              <fn id="ebs.TF.1.7">
                <label>7. </label>
                <p>For further information on the proportion of each EBS subtype caused by pathogenic variants in <italic toggle="yes">KRT5</italic> and <italic toggle="yes">KRT14</italic>, see <xref ref-type="table" rid="ebs.T.molecular_basis_of_ebs_types_cause">Table 3</xref>.</p>
              </fn>
              <fn id="ebs.TF.1.8">
                <label>8. </label>
                <p><xref ref-type="bibr" rid="ebs.REF.yasukawa.2006.313">Yasukawa et al [2006]</xref>, <xref ref-type="bibr" rid="ebs.REF.rugg.2007.574">Rugg et al [2007]</xref>, <xref ref-type="bibr" rid="ebs.REF.bolling.2011.637">Bolling et al [2011]</xref></p>
              </fn>
              <fn id="ebs.TF.1.9">
                <label>9. </label>
                <p>Approximately 90%-95% of individuals with EBS-MP will have the <xref ref-type="table" rid="ebs.T.pathogenic_krt5_variants_discussed">p.Pro25Leu</xref> pathogenic variant in <italic toggle="yes">KRT5</italic> [<xref ref-type="bibr" rid="ebs.REF.pascucci.2006.620">Pascucci et al 2006</xref>, <xref ref-type="bibr" rid="ebs.REF.shurman.2006.132">Shurman et al 2006</xref>]. <xref ref-type="bibr" rid="ebs.REF.horiguchi.2005.83">Horiguchi et al [2005]</xref> describe a second pathogenic variant associated with EBS-MP.</p>
              </fn>
              <fn id="ebs.TF.1.10">
                <label>10. </label>
                <p>Approximately 2%-5% of individuals with EMB-MP have a <xref ref-type="table" rid="ebs.T.pathogenic_krt14_variants_discusse">p.Met119Thr</xref> pathogenic variant in <italic toggle="yes">KRT14</italic> [<xref ref-type="bibr" rid="ebs.REF.harel.2006.1654">Harel et al 2006</xref>].</p>
              </fn>
              <fn id="ebs.TF.1.11">
                <label>11. </label>
                <p>A common founder variant in the catalytic domain, <xref ref-type="table" rid="ebs.T.tgm5_variants_discussed_in_this_ge">p.Gly113Cys</xref>, has been found in the European population.</p>
              </fn>
              <fn id="ebs.TF.1.12">
                <label>12. </label>
                <p>Because only approximately 75% of individuals with biopsy-proven EBS have identifiable heterozygous (or rarely biallelic) pathogenic variants in <italic toggle="yes">KRT5</italic> or <italic toggle="yes">KRT14</italic>, it is possible that pathogenic variants in another as-yet unidentified gene are also causative [<xref ref-type="bibr" rid="ebs.REF.yasukawa.2006.313">Yasukawa et al 2006</xref>, <xref ref-type="bibr" rid="ebs.REF.rugg.2007.574">Rugg et al 2007</xref>, <xref ref-type="bibr" rid="ebs.REF.bolling.2011.637">Bolling et al 2011</xref>]. Note: Two individuals with features of EBS caused by biallelic pathogenic variants in <italic toggle="yes">DST</italic>, encoding dystonin, have been reported [<xref ref-type="bibr" rid="ebs.REF.groves.2010.1551">Groves et al 2010</xref>, <xref ref-type="bibr" rid="ebs.REF.liu.2012.742">Liu et al 2012</xref>]. More recent studies from the Netherlands identified a heterozygous pathogenc variant in <italic toggle="yes">PLEC</italic> in six of 16 individuals with biopsy-proven EBS who did not have a pathogenic variant detected in <italic toggle="yes">KRT5</italic> or <italic toggle="yes">KRT14</italic> [<xref ref-type="bibr" rid="ebs.REF.bolling.2014.273">Bolling et al 2014</xref>].</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Skin biopsy.</bold> Immunofluorescence antigenic mapping has been the <italic toggle="yes">sine qua non</italic> for the diagnosis of EBS because of its rapid turnaround time and high sensitivity and specificity [<xref ref-type="bibr" rid="ebs.REF.yiasemides.2006.387">Yiasemides et al 2006</xref>]. However, advances in molecular genetic testing have lead clinicians to use genetic testing for diagnosis, as opposed to skin biopsy. Skin biopsy should still be considered in the evaluation of newborns with extensive blistering and erosions, in cases where the EB phenotype is not clear and a prompt diagnosis is needed, and when genetic testing is not available.</p>
          <list list-type="bullet">
            <list-item>
              <p>Biopsy technique</p>
              <list list-type="bullet">
                <list-item>
                  <p>To insure the most accurate diagnosis, the leading edge of a fresh blister induced by mechanical friction should be biopsied. The healing in non-induced intact blisters may obscure the morphology.</p>
                </list-item>
                <list-item>
                  <p>Induced blisters are typically analyzed by light microscopy, immunofluorescent microscopy, and transmission electron microscopy.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Histology (light microscopy)</p>
              <list list-type="bullet">
                <list-item>
                  <p>In all cases of EBS, splitting is observed within or above the basal cell layer of the skin. Routine histology suggests the diagnosis of EB but is an inadequate and unacceptable test for accurately diagnosing the EB type and subtype. It is most valuable to rule out other causes of blistering when the differential diagnosis is broad.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Transmission electron microscopy</p>
              <list list-type="bullet">
                <list-item>
                  <p>In cases of EBS caused by biallelic pathogenic variants in <italic toggle="yes">EXPH5</italic>, widened space between keratinocytes, aggregation of keratin filaments, and vesicles near the plasma membrane and nucleus have been reported [<xref ref-type="bibr" rid="ebs.REF.mcgrath.2012.1115">McGrath et al 2012</xref>].</p>
                </list-item>
                <list-item>
                  <p>In EBS-gen sev, the keratin intermediate filaments (also called tonofilaments) are clumped, a finding that serves as a distinguishing feature [<xref ref-type="bibr" rid="ebs.REF.bergman.2007.463">Bergman et al 2007</xref>]. This finding is only seen using electron microscopy, making this study useful when the diagnosis of EBS-gen sev is suspected. The absence of keratin intermediate filaments is a distinguishing feature of autosomal recessive EBS caused by biallelic pathogenic variants in <italic toggle="yes">KRT14</italic> (EBS-AR K14).</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Immunofluorescence microscopy</p>
              <list list-type="bullet">
                <list-item>
                  <p>In most cases of EBS, diagnosis using immunofluorescent microscopy is made by mapping the blister. Antibodies to keratin 5 or keratin 14 and other dermal-epidermal junction antigens (typically laminin 332 and type VII collagen) show localization of stained epitopes to the blister floor. This mapping pattern is specific to EBS but does not further delineate the EBS subtype. It also relies on the formation of a blister in the biopsy specimen. Thus, there is a risk in affected individuals with less severe disease that a blister may not be induced and the biopsy may be non-diagnostic.</p>
                </list-item>
                <list-item>
                  <p>Immunofluorescent microscopy can be helpful in the diagnosis of autosomal recessive forms of EBS, as the affected protein will be substantially reduced or absent. However, antibodies to exophilin 5 and transglutaminase 5 are not widely available, limiting the clinical utility of this study to the exceedingly rare forms of EBS-AR caused by biallelic pathogenic variants in <italic toggle="yes">KRT14</italic>.</p>
                </list-item>
              </list>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec id="ebs.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="ebs.Clinical_Description">
          <title>Clinical Description</title>
          <p>The most common forms of epidermolysis bullosa simplex (EBS) are subdivided into clinical phenotypes &#x02014; EBS, localized (EBS-loc) (previously known as EBS, Weber-Cockayne type); EBS, generalized intermediate (EBS-gen intermed) (previously known as EBS, Koebner type); EBS-with mottled pigmentation (EBS-MP); and EBS, generalized severe (EBS-gen sev, previously known as EBS, Dowling-Meara) &#x02014; based primarily on dermatologic and histopathologic findings. Although it is now recognized that these phenotypes are part of a continuum with overlapping features, it is reasonable to continue to think of EBS in terms of the phenotypes in order to provide affected individuals with information about the expected clinical course. The clinical features of these disorders are summarized in <xref ref-type="table" rid="ebs.T.diagnostic_clinical_features_of_th">Table 2</xref>.</p>
          <table-wrap id="ebs.T.diagnostic_clinical_features_of_th" orientation="portrait" position="anchor">
            <label>Table 2. </label>
            <caption>
              <p>Diagnostic Clinical Features of the Four Most Common Subtypes of EBS</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_1" valign="middle" colspan="3" align="left" scope="colgroup" rowspan="1">EBS Subtype</th>
                  <th id="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Localized</th>
                  <th id="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Generalized Intermediate</th>
                  <th id="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Mottled Pigmentation</th>
                  <th id="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_5" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Generalized Severe</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_1" valign="middle" colspan="3" align="left" scope="row" rowspan="1">
                    <bold>Age of Onset</bold>
                  </td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Infancy, usually by 12-18 months</td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Birth/infancy</td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Birth/infancy</td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Birth</td>
                </tr>
                <tr>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_1" rowspan="7" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Clinical<break/>Feature</bold>
                  </td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_1" rowspan="3" valign="middle" align="left" colspan="1">
                    <bold>Blisters</bold>
                  </td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">
                    <bold>Distribution</bold>
                  </td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Usually limited to hands, feet; can occur at sites of repeated trauma (e.g., belt line)</td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Generalized</td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Generalized</td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Generalized</td>
                </tr>
                <tr>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">
                    <bold>Grouped (herpetiform)</bold>
                  </td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">No</td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">No</td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sometimes</td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Yes</td>
                </tr>
                <tr>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">
                    <bold>Mucosal</bold>
                  </td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Rare</td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Occasionally</td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Occasionally</td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Often</td>
                </tr>
                <tr>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_1" valign="middle" colspan="2" align="left" scope="row" rowspan="1">
                    <bold>Hyperkeratosis of palms &#x00026; soles (keratoderma)</bold>
                  </td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Occasionally</td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Occasionally</td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Common, focal</td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Common, progressive</td>
                </tr>
                <tr>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_1" valign="middle" colspan="2" align="left" scope="row" rowspan="1">
                    <bold>Nail involvement</bold>
                  </td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Occasionally</td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Occasionally</td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Occasionally</td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Common</td>
                </tr>
                <tr>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_1" valign="middle" colspan="2" align="left" scope="row" rowspan="1">
                    <bold>Milia</bold>
                  </td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Rare</td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Occasionally</td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Unknown</td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Common</td>
                </tr>
                <tr>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_1" valign="middle" colspan="2" align="left" scope="row" rowspan="1">
                    <bold>Hyper/ hypopigmentation</bold>
                  </td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">No</td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Can occur</td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Always</td>
                  <td headers="hd_h_ebs.T.diagnostic_clinical_features_of_th_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Common</td>
                </tr>
              </tbody>
            </table>
          </table-wrap>
          <sec id="ebs.EBS_Localized_EBSloc">
            <title>EBS, Localized (EBS-loc)</title>
            <p>Blisters begin in infancy and can present at birth; severity is usually mild. The first episodes may occur on the knees and shins with crawling or on the feet at approximately age 12-18 months, after walking is firmly established. Some affected individuals do not manifest the disease until adolescence or early adult life.</p>
            <p>Although blisters are usually confined to the hands and feet, they can occur anywhere given adequate trauma; for example, blisters can develop on the buttocks after horseback riding and around the waist after wearing a tight belt. The palms and soles are usually more involved than the backs of the hands and the tops of the feet. Symptoms are worse in warm weather and worsen with sweating. Hyperkeratosis of the palms and soles can develop in later childhood and adult life. Occasionally, a large blister in a nail bed may result in shedding of the nail.</p>
          </sec>
          <sec id="ebs.EBS_Generalized_Intermediate_EBSgen">
            <title>EBS, Generalized Intermediate (EBS-gen intermed)</title>
            <p>Blisters may be present at birth or develop within the first few months of life. EBS-gen intermed is distinguished from EBS-loc by its more widespread involvement and from EBS-sev gen by absence of clumped keratin intermediate filaments in basal keratinocytes on electron microscopy (see <xref ref-type="sec" rid="ebs.Establishing_the_Diagnosis">Establishing the Diagnosis</xref>, <bold>Skin biopsy</bold>). In general, EBS-gen intermed is milder than EBS-sev gen, but clinical overlap is high. Similarly, mild EBS-gen intermed can be indistinguishable from EBS-loc. Branches of one large pedigree were reported separately as EBS-Koebner (now EBS-gen intermed) and EBS-Weber Cockayne (now EBS-loc), reflecting the variability in severity even within families.</p>
          </sec>
          <sec id="ebs.EBS_with_Mottled_Pigmentation_EBSMP">
            <title>EBS with Mottled Pigmentation (EBS-MP)</title>
            <p>Skin fragility in EBS-MP is evident at birth and is clinically indistinguishable from generalized forms of EBS. Small hyperpigmented macules begin to appear in early childhood, progress over time, and coalesce to a reticulate pattern. Hypopigmented macules may be interspersed. These changes tend to develop on the trunk (particularly in large skin folds such as the neck, groin, and axillae) and then on the extremities. The pigmentation does not occur in areas of blistering (a factor distinguishing it from post-inflammatory hyperpigmentation and hypopigmentation) and often disappears in adult life. Focal palmar and plantar hyperkeratoses may occur.</p>
          </sec>
          <sec id="ebs.EBS_Generalized_Severe_EBSgen_sev">
            <title>EBS, Generalized Severe (EBS-gen sev)</title>
            <p>Onset is usually at birth and severity varies greatly both within and between families. Blistering can be severe enough to result in neonatal or infant death. Widespread and severe blistering and/or multiple grouped clumps of small blisters (whose resemblance to the blisters of herpetic infection gave the disorder one of its names) are typical. Hemorrhagic blisters are common. The mucosa can be involved; this usually improves with age.</p>
            <p>Decreased frequency of blistering occurs during mid- to late childhood and blistering may be a minimal component of the disorder in adult life.</p>
            <p>Progressive hyperkeratosis (punctate or diffuse) of the palms and soles begins in childhood and may be the major complaint of affected individuals in adult life. Nail dystrophy (thickened, deformed nails) is common. Both hyper- and hypopigmentation can occur, typically in areas of blistering. Mucosal involvement in EBS-gen sev may interfere with feeding. Laryngeal involvement, manifesting as a hoarseness, can also occur, but is not life threatening.</p>
          </sec>
          <sec id="ebs.Cancer_Risk">
            <title>Cancer Risk</title>
            <p>Squamous cell carcinoma is not usually associated with EBS.</p>
          </sec>
        </sec>
        <sec id="ebs.Phenotype_Correlations_by_Gene">
          <title>Phenotype Correlations by Gene</title>
          <p>The proportion of <italic toggle="yes">EXPH5</italic>, <italic toggle="yes">KRT5</italic>, <italic toggle="yes">KRT14</italic>, and <italic toggle="yes">TGM5</italic> pathogenic variants responsible for each phenotype is shown in <xref ref-type="table" rid="ebs.T.molecular_basis_of_ebs_types_cause">Table 3</xref>. Clinical overlap between EBS-gen intermed and EBS-gen sev is substantial; thus, much of the molecular genetic data have been lumped in the literature and the proportions presented in the table are necessarily imprecise. In addition, predominance of pathogenic variants in <italic toggle="yes">KRT5</italic> or <italic toggle="yes">KRT14</italic> may be population specific [<xref ref-type="bibr" rid="ebs.REF.abu_sad.2006.777">Abu Sa'd et al 2006</xref>, <xref ref-type="bibr" rid="ebs.REF.yasukawa.2006.313">Yasukawa et al 2006</xref>, <xref ref-type="bibr" rid="ebs.REF.rugg.2007.574">Rugg et al 2007</xref>].</p>
          <table-wrap id="ebs.T.molecular_basis_of_ebs_types_cause" orientation="portrait" position="anchor">
            <label>Table 3. </label>
            <caption>
              <p>Molecular Basis of EBS Types Caused by EXPH5, <italic toggle="yes">KRT5</italic>, <italic toggle="yes">KRT14</italic><bold>,</bold> and <italic toggle="yes">TGM5</italic> Pathogenic Variants</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_1">Phenotype</th>
                  <th id="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_2">% of all EBS</th>
                  <th id="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_3" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_3">Inheritance</th>
                  <th id="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_4" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_4">Severity</th>
                  <th id="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5" valign="middle" colspan="4" align="left" scope="colgroup" rowspan="1">Proportion of Pathogenic Variants</th>
                </tr>
                <tr>
                  <th headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5" id="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">
                    <italic toggle="yes">EXPH5</italic>
                  </th>
                  <th headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5" id="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">
                    <italic toggle="yes">KRT5</italic>
                  </th>
                  <th headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5" id="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">
                    <italic toggle="yes">KRT14</italic>
                  </th>
                  <th headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5" id="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">
                    <italic toggle="yes">TGM5</italic>
                  </th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <bold>EBS-loc</bold>
                  </td>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">60%</td>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AD</td>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_4" rowspan="2" valign="middle" align="left" colspan="1">Mild</td>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_1" rowspan="2" valign="middle" align="left" colspan="1">1%-2%</td>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_2" rowspan="2" valign="middle" align="left" colspan="1">&#x0003c;47%</td>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_3" rowspan="2" valign="middle" align="left" colspan="1">&#x0003e;47%</td>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_4" rowspan="2" valign="middle" align="left" colspan="1">5%</td>
                </tr>
                <tr>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">&#x0003c;1%</td>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                </tr>
                <tr>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>EBS-gen intermed</bold>
                  </td>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">15%</td>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_3" rowspan="3" valign="middle" align="left" colspan="1">AD</td>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_4" rowspan="3" valign="middle" align="left" colspan="1">Moderate-severe</td>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">NI</td>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;50%</td>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;50%</td>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_4" valign="middle" align="left" rowspan="1" colspan="1">NI</td>
                </tr>
                <tr>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>EBS-gen sev</bold>
                  </td>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">25%</td>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_1" valign="middle" colspan="1" align="left" rowspan="1">NI</td>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;50%</td>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;50%</td>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_4" valign="middle" align="left" rowspan="1" colspan="1">NI</td>
                </tr>
                <tr>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>EBS-MP</bold>
                  </td>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;1%</td>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_1" valign="middle" colspan="1" align="left" rowspan="1">&#x0003c;1%&#x000a0;<sup>1</sup></td>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">94%&#x000a0;<sup>2</sup></td>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">5%</td>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_4" valign="middle" align="left" rowspan="1" colspan="1">NI</td>
                </tr>
                <tr>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>All EBS</bold>
                  </td>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">100%</td>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">1%-2%</td>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">47%</td>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">47%</td>
                  <td headers="hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_1_5 hd_h_ebs.T.molecular_basis_of_ebs_types_cause_1_1_2_4" valign="middle" align="left" rowspan="1" colspan="1">5%</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>In 25% of biopsy proven EBS, no pathogenic variant in <italic toggle="yes">KRT5</italic> or <italic toggle="yes">KRT14</italic> could be identified [<xref ref-type="bibr" rid="ebs.REF.bolling.2010.1388">Bolling et al 2010</xref>]; molecular genetic testing of <italic toggle="yes">EXPH5</italic> and <italic toggle="yes">TGM5</italic> was not performed in this study. Further studies from the Netherlands identified a heterozygous pathogenc variant in <italic toggle="yes">PLEC</italic> in six of 16 individuals with biopsy-proven EBS who did not have a pathogenic variant detected in <italic toggle="yes">KRT5</italic> or <italic toggle="yes">KRT14</italic> [<xref ref-type="bibr" rid="ebs.REF.bolling.2014.273">Bolling et al 2014</xref>].</p>
              </fn>
              <fn>
                <p>NI = no information</p>
              </fn>
              <fn id="ebs.TF.3.1">
                <label>1. </label>
                <p>
                  <xref ref-type="bibr" rid="ebs.REF.turcan.2016.1137">Turcan et al [2016]</xref>
                </p>
              </fn>
              <fn id="ebs.TF.3.2">
                <label>2. </label>
                <p><xref ref-type="bibr" rid="ebs.REF.hamada.2004.609">Hamada et al [2004]</xref>, <xref ref-type="bibr" rid="ebs.REF.horiguchi.2005.83">Horiguchi et al [2005]</xref></p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
        <sec id="ebs.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p><bold><italic toggle="yes">EXPH5</italic>.</bold> Pathogenic variants in <italic toggle="yes">EXPH5</italic> are rare, with only seven cases reported to date. All reported pathogenic variants resulting in <italic toggle="yes">EXPH5-</italic>related EBS are loss-of-function variants that can be located anywhere in the gene.</p>
          <p><bold><italic toggle="yes">KRT5</italic> and <italic toggle="yes">KRT14</italic>.</bold> A moderate correlation exists between the EBS phenotypes and the functional domain of either <italic toggle="yes">KRT5</italic> or <italic toggle="yes">KRT14</italic> in which the pathogenic variant is located [reviewed in <xref ref-type="bibr" rid="ebs.REF.irvine.2003.1">Irvine &#x00026; McLean 2003</xref>, <xref ref-type="bibr" rid="ebs.REF.m_ller.2006.719">M&#x000fc;ller et al 2006</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>Pathogenic variants in the nonhelical linker segments (L1 and L2) and in the 1A segment of the rod domain are associated with EBS-loc.</p>
            </list-item>
            <list-item>
              <p>Pathogenic variants in the 1A or 2B segments of the rod domain of <italic toggle="yes">KRT5</italic> and <italic toggle="yes">KRT14</italic> are common for EBS-gen intermed.</p>
            </list-item>
            <list-item>
              <p>Pathogenic variants in the beginning of the 1A or the end of the 2B segments of the rod domain of <italic toggle="yes">KRT5</italic> and beginning of the 1A or 2B segments of the rod domain of <italic toggle="yes">KRT5</italic> and <italic toggle="yes">KRT14</italic> are typical in EBS-gen sev.</p>
            </list-item>
            <list-item>
              <p>The <xref ref-type="table" rid="ebs.T.pathogenic_krt5_variants_discussed">p.Pro25Leu</xref> and <xref ref-type="table" rid="ebs.T.pathogenic_krt5_variants_discussed">c.1649delG</xref> pathogenic variants in <italic toggle="yes">KRT5</italic> are associated with EBS-MP. Two pathogenic variants are described in <italic toggle="yes">KRT14</italic> [see <xref ref-type="bibr" rid="ebs.REF.harel.2006.1654">Harel et al 2006</xref>, <xref ref-type="bibr" rid="ebs.REF.arin.2010.1365">Arin et al 2010</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="ebs.Penetrance">
          <title>Penetrance</title>
          <p>Penetrance is 100% for known heterozygous (autosomal dominant) and biallelic (autosomal recessive) <italic toggle="yes">KRT5</italic> and <italic toggle="yes">KRT14</italic> pathogenic variants. Penetrance is also 100% for known biallelic pathogenic variants in <italic toggle="yes">EXPH5</italic> and <italic toggle="yes">TGM5</italic>. Disease severity may be influenced by other factors and may show intrafamilial variation [<xref ref-type="bibr" rid="ebs.REF.indelman.2005.272">Indelman et al 2005</xref>].</p>
        </sec>
        <sec id="ebs.Nomenclature">
          <title>Nomenclature</title>
          <p>In 1886, Koebner coined the term epidermolysis bullosa hereditaria. In the late nineteenth and early twentieth centuries, Brocq and Hallopeau coined the terms traumatic pemphigus, congenital traumatic blistering, and acantholysis bullosa; these terms are no longer in use [<xref ref-type="bibr" rid="ebs.REF.fine.1999">Fine et al 1999</xref>].</p>
          <p>The nomenclature for EBS has changed four times in the last fifteen years. The eponyms EBS-Weber-Cockayne and EBS-Koebner were changed to EBS, localized and EBS-other generalized in the 2008 classification system [<xref ref-type="bibr" rid="ebs.REF.fine.2008.931">Fine et al 2008</xref>]. The most recent classification system, referred to as the &#x0201c;onion skin&#x0201d; terminology, arose from the most recent international consensus meeting, the recommendations of which were published in June 2014 [<xref ref-type="bibr" rid="ebs.REF.fine.2014.1103">Fine et al 2014</xref>]. This classification system expands on the histologic description and specific pathogenic variants found in affected individuals (see <xref ref-type="table" rid="ebs.T.comparison_of_2008_nomenclature_wi">Table 4</xref>).</p>
          <table-wrap id="ebs.T.comparison_of_2008_nomenclature_wi" orientation="portrait" position="anchor">
            <label>Table 4. </label>
            <caption>
              <p>Comparison of 2008 Nomenclature with Proposed &#x0201c;Onion Skin&#x0201d; Terminology&#x02014;Representative Examples</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_ebs.T.comparison_of_2008_nomenclature_wi_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">Old Name (per 2008 recommendations)</th>
                  <th id="hd_h_ebs.T.comparison_of_2008_nomenclature_wi_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">2014 Nomenclature</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_ebs.T.comparison_of_2008_nomenclature_wi_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">EBS, localized</td>
                  <td headers="hd_h_ebs.T.comparison_of_2008_nomenclature_wi_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">EBS localized, normal keratin 5 and 14 staining, <italic toggle="yes">KRT5</italic> or <italic toggle="yes">KRT14</italic> pathogenic variant (specify type)</td>
                </tr>
                <tr>
                  <td headers="hd_h_ebs.T.comparison_of_2008_nomenclature_wi_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">EBS, Dowling-Meara</td>
                  <td headers="hd_h_ebs.T.comparison_of_2008_nomenclature_wi_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">EBS generalized severe, normal keratin 5 and 14 staining, <italic toggle="yes">KRT5</italic> or <italic toggle="yes">KRT14</italic> pathogenic variant (specify type)</td>
                </tr>
                <tr>
                  <td headers="hd_h_ebs.T.comparison_of_2008_nomenclature_wi_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">EBS, generalized other</td>
                  <td headers="hd_h_ebs.T.comparison_of_2008_nomenclature_wi_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">EBS generalized intermediate, normal keratin 5 and 14 staining, <italic toggle="yes">KRT5</italic> or <italic toggle="yes">KRT14</italic> pathogenic variant (specify type)</td>
                </tr>
                <tr>
                  <td headers="hd_h_ebs.T.comparison_of_2008_nomenclature_wi_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">EBM-MP</td>
                  <td headers="hd_h_ebs.T.comparison_of_2008_nomenclature_wi_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">EBS-MP, normal keratin 5 staining, <italic toggle="yes">KRT5</italic> pathogenic variant (specify type)</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>EBS = epidermolysis bullosa simplex</p>
              </fn>
              <fn>
                <p>MP = mottled pigmentation</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
        <sec id="ebs.Prevalence">
          <title>Prevalence</title>
          <p>The prevalence of EBS is uncertain; estimates range from 1:30,000 to 1:50,000. EBS-loc is most prevalent as it does not result in neonatal death and interferes least with fitness. EBS-gen sev and EBS-gen intermed are rare, and EBS-MP is even rarer.</p>
          <p>The experience of the National Epidermolysis Bullosa Registry (NEBR) suggests that ascertainment is highly biased and incomplete. Horn and colleagues estimate a prevalence of 28.6 per million in Scotland, and prevalence estimates from other countries range from one to 28 per million [<xref ref-type="bibr" rid="ebs.REF.horn.1997.560">Horn et al 1997</xref>].</p>
        </sec>
      </sec>
      <sec id="ebs.Genetically_Related_Allelic_Disorder">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with pathogenic variants in <italic toggle="yes">EXPH5</italic>.</p>
        <p><bold><italic toggle="yes">KRT5</italic>.</bold> Dowling-Degos disease (DDD), characterized by progressive and disfiguring reticulate hyperpigmentation of the flexures, is caused by heterozygous <italic toggle="yes">KRT5</italic> loss-of-function variants [<xref ref-type="bibr" rid="ebs.REF.betz.2006.510">Betz et al 2006</xref>, <xref ref-type="bibr" rid="ebs.REF.liao.2007.298">Liao et al 2007</xref>]. Galli-Galli disease, a variant of DDD that exhibits the same hyperpigmentation pattern accompanied by acantholytic lesions, is also caused by heterozygous <italic toggle="yes">KRT5</italic> loss-of-function variants [<xref ref-type="bibr" rid="ebs.REF.sprecher.2007.572">Sprecher et al 2007</xref>, <xref ref-type="bibr" rid="ebs.REF.hanneken.2010.197">Hanneken et al 2010</xref>]. Inheritance is autosomal dominant.</p>
        <p><bold><italic toggle="yes">KRT14</italic>.</bold> Naegeli-Franceschetti-Jadassohn syndrome (NFJS) and dermatopathia pigmentosa reticularis (DPR) are phenotypically similar ectodermal dysplasia syndromes characterized by complete absence of dermatoglyphics (fingerprint lines), a reticulate pattern of skin hyperpigmentation, thickening of the palms and soles (palmoplantar keratoderma), abnormal sweating, and other subtle developmental anomalies of the teeth, hair, and skin. Inheritance is autosomal dominant. Heterozygous pathogenic nonsense or frameshift variants in the E1/V1-encoding region of <italic toggle="yes">KRT14</italic> have been identified, indicating that KRT14 haploinsufficiency resulting in increased susceptibility of keratinocytes to pro-apoptotic signals is causative [<xref ref-type="bibr" rid="ebs.REF.lugassy.2006.724">Lugassy et al 2006</xref>, <xref ref-type="bibr" rid="ebs.REF.lugassy.2008.1517">Lugassy et al 2008</xref>].</p>
        <p><bold><italic toggle="yes">TGM5.</italic></bold> Biallelic pathogenic variants in <italic toggle="yes">TGM5</italic> can cause EBS-acral peeling skin syndrome (PSS2; OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://omim.org/entry/609796">609796</ext-link>). The condition is characterized by skin peeling in an acral distribution (i.e., affecting most often the dorsum of the hands and feet). Some affected individuals do in fact have blisters and occasionally this condition can be confused with EBS caused by a heterozygous pathogenic variant in <italic toggle="yes">KRT5</italic> or <italic toggle="yes">KRT14</italic>.</p>
      </sec>
      <sec id="ebs.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>According to the 2014 classification system, the four major types of epidermolysis bullosa (EB), caused by pathogenic variants in 18 different genes, are EB simplex (EBS), junctional EB (JEB), dystrophic EB (DEB), and Kindler syndrome [<xref ref-type="bibr" rid="ebs.REF.fine.2014.1103">Fine et al 2014</xref>]. Classification into major type is based on the location of blistering in relation to the dermal-epidermal junction of skin. Subtypes are predominantly determined by clinical features and supported by molecular diagnosis.</p>
        <p>The four major types of EB share easy fragility of the skin (and mucosa in many cases), manifested by blistering with little or no trauma. Although clinical examination is useful in determining the extent of blistering and the presence of oral and other mucous membrane lesions, defining characteristics such as the presence and extent of scarring &#x02014; especially in young children and neonates &#x02014; may not be established or significant enough to allow identification of EB type; thus, molecular genetic testing (or less commonly skin biopsy) is usually required to establish the most precise diagnosis. The ability to induce blisters with friction (although the amount of friction can vary) and to enlarge blisters by applying pressure to the blister edge is common to all; mucosal and nail involvement and the presence or absence of milia may not be helpful discriminators.</p>
        <p>Post-inflammatory changes, such as those seen in EBS-sev gen, are often mistaken for scarring or mottled pigmentation. Scarring can occur in simplex and junctional EB as a result of infection of erosions or scratching, which further damages the exposed surface. Congenital absence of the skin can be seen in any of the four major types of EB and is not a discriminating diagnostic feature.</p>
        <p>Corneal erosions, esophageal strictures, and nail and tooth enamel involvement may indicate either DEB or JEB. In milder cases, scarring (especially of the dorsal hands and feet) suggests DEB. Pseudosyndactyly (mitten deformities) resulting from scarring of the hands and feet in older children and adults usually suggests DEB.</p>
        <p><bold>Other subtypes of EB</bold>
<bold>simplex</bold>
<bold>(EBS).</bold> The 2014 classification system divides EBS into two subtypes based on the location of blistering in the epidermis. In the <bold>suprabasal</bold> forms of EBS, blistering occurs above the basal keratinocytes. The suprabasal forms of EBS include: EBS superficialis; EBS acantholytic; and skin fragility syndromes resulting from deficiencies of desmoplakin, plakoglobin, or plakophilin.</p>
        <list list-type="bullet">
          <list-item>
            <p>Acantholytic EBS is caused by biallelic pathogenic variants in the tail region of <italic toggle="yes">DSP</italic>, which encodes desmoplakin [<xref ref-type="bibr" rid="ebs.REF.jonkman.2005.653">Jonkman et al 2005</xref>, <xref ref-type="bibr" rid="ebs.REF.bolling.2010.1388">Bolling et al 2010</xref>, <xref ref-type="bibr" rid="ebs.REF.hobbs.2010.2680">Hobbs et al 2010</xref>]. Affected neonates present with progressive erosions without blistering, alopecia, or loss of nails. Death within the first days after birth secondary to profound fluid and electrolyte imbalance is common.</p>
          </list-item>
          <list-item>
            <p>EBS-plakophilin (skin fragility-ectodermal dysplasia syndrome) is characterized by mild skin fragility associated with perioral cracking and cheilitis, hypotrichosis or alopecia, and a painful and fissured palmoplantar keratoderma; it is caused by biallelic loss-of-function variants in <italic toggle="yes">PKP1</italic> (for review, see <xref ref-type="bibr" rid="ebs.REF.mcgrath.2010.125">McGrath &#x00026; Mellerio [2010]</xref>).</p>
          </list-item>
        </list>
        <p>In the <bold>basal</bold> forms of EBS, blistering occurs within the basal keratinocytes. The most common subtypes of basal EBS are the subject of this <italic toggle="yes">GeneReview</italic>. Other rare forms of basal EBS in the 2014 classification are: EBS, migratory circinate (EBS-migr); EBS with muscular dystrophy (EBS-MD); EBS with pyloric atresia (EBS-PA); EBS-Ogna (EBS-Og); and EBS, autosomal recessive-BP230 deficiency (EBS-AR BP230).</p>
        <p><bold>EB caused by pathogenic variants in <italic toggle="yes">PLEC</italic>.</bold> Biallelic and heterozygous pathogenic variants in <italic toggle="yes">PLEC</italic>, the gene encoding plectin, which is located in the hemidesmosomes of the basement membrane zone of skin and muscle cells, cause cleavage in the basal keratinocyte layer. Hence, these disorders are classified as EBS in the 2014 classification system. In most cases, the associated phenotypes (i.e., EB with muscular dystrophy, EB with pyloric atresia) are more complex:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>EB with muscular dystrophy</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/226670">226670</ext-link>). Some individuals with EB resulting from biallelic pathogenic variants in <italic toggle="yes">PLEC1</italic> develop muscular dystrophy either in childhood or later in life [<xref ref-type="bibr" rid="ebs.REF.smith.1996.450">Smith et al 1996</xref>, <xref ref-type="bibr" rid="ebs.REF.shimizu.1999.950">Shimizu et al 1999</xref>, <xref ref-type="bibr" rid="ebs.REF.charlesworth.2003.1344">Charlesworth et al 2003</xref>, <xref ref-type="bibr" rid="ebs.REF.kossharnes.2004.124">Koss-Harnes et al 2004</xref>, <xref ref-type="bibr" rid="ebs.REF.schara.2004.218">Schara et al 2004</xref>, <xref ref-type="bibr" rid="ebs.REF.pfendner.2005a.241">Pfendner et al 2005a</xref>]. Within basal keratinocytes, plectin is localized to the inner plaques of the hemidesmosomes, which are hypoplastic and show poor association with keratin filaments. Electron microscopy of skin biopsies reveals a plane of cleavage (level of separation) within the bottom layer of the basal keratinocytes, just above the hemidesmosomes. Inheritance is autosomal recessive.</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="eb-pa" document-type="chapter"><bold>EB with pyloric atresia</bold></related-object> is associated with biallelic premature termination pathogenic variants in <italic toggle="yes">PLEC.</italic> An identical phenotype is seen in JEB with pyloric atresia caused by the genes encoding alpha 6 integrin <italic toggle="yes">(ITGA6</italic>) or beta 4 integrin <italic toggle="yes">(ITGB4</italic>) [<xref ref-type="bibr" rid="ebs.REF.nakamura.2005.28">Nakamura et al 2005</xref>, <xref ref-type="bibr" rid="ebs.REF.pfendner.2005.111">Pfendner &#x00026; Uitto 2005</xref>]. Disease course is severe and usually lethal in the neonatal period. Inheritance is autosomal recessive.</p>
          </list-item>
          <list-item>
            <p><bold>EB-Ogna</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/131950">131950</ext-link>) was originally described in one Norwegian and one German family and is caused by a heterozygous site-specific pathogenic missense variant within the rod domain of <italic toggle="yes">PLEC</italic> [<xref ref-type="bibr" rid="ebs.REF.kossharnes.2002.87">Koss-Harnes et al 2002</xref>]. In these cases, transmission electron microscopy of a skin biopsy identified the cleavage plane to be just above the inner plates of the hemidesmosomes in the deep basal cell cytoplasm. Immunofluorescence staining of a skin biopsy showed reduced and/or patchy plectin staining. Inheritance is autosomal dominant. More recent work by <xref ref-type="bibr" rid="ebs.REF.bolling.2014.273">Bolling and colleagues [2014]</xref> in the Netherlands demonstrated that approximately 40% of individuals with biopsy-proven EBS who lack identifiable pathogenic variants in <italic toggle="yes">KRT5</italic> or <italic toggle="yes">KRT14</italic> have a heterozygous pathogenic variant in <italic toggle="yes">PLEC</italic>. This work suggests that mutation of <italic toggle="yes">PLEC1</italic> may be more common than previously realized.</p>
          </list-item>
        </list>
        <p><related-object link-type="booklink" source-id="gene" document-id="ebj" document-type="chapter"><bold>Junctional EB</bold></related-object>
<bold>(JEB)</bold> is characterized by fragility of the skin and mucous membranes, manifest by blistering with little or no trauma. Blistering may be severe and granulation tissue can form on the skin around the oral and nasal cavities, fingers, and toes, and internally around the upper airway. Blisters generally heal with no significant scarring. The broad classification of JEB is divided into generalized and localized major subtypes with subordinate phenotypic subtypes. JEB, generalized includes: JEB, generalized severe (JEN-gen sev, formerly Herlitz JEB); JEN, generalized intermediate (JEB-gen intermed); JEN with pyloric atresia (JEB-PA); JEB-late onset (JEB-LO); and JEB with respiratory and renal involvement (JEB-RR). In JEB-gen sev, the classic severe form of JEB, blisters are present at birth or become apparent in the neonatal period. Congenital malformations of the urinary tract and bladder may also occur. In JEB-gen intermed, the phenotype may be milder with blistering localized to hands, feet, knees, and elbows with or without renal or ureteral involvement. Some individuals never blister after the newborn period. Additional features shared by JEB and the other major forms of epidermolysis bullosa (EB) include congenital localized absence of skin (aplasia cutis congenita), milia, nail dystrophy, scarring alopecia, hypotrichosis, and joint contractures. Biallelic pathogenic variants in one of the following four genes are known to cause JEB: <italic toggle="yes">LAMB3</italic> (70% of all JEB), <italic toggle="yes">COL17A1</italic> (12%), <italic toggle="yes">LAMC2</italic> (9%), and <italic toggle="yes">LAMA3</italic> (9%).</p>
        <p>JEB with pyloric atresia has been associated with biallelic pathogenic variants in either &#x003b1;<sub>6</sub>&#x003b2;<sub>4</sub> integrin or plectin (see <related-object link-type="booklink" source-id="gene" document-id="eb-pa" document-type="chapter"><bold>EBS with pyloric atresia</bold></related-object>); inheritance is autosomal recessive.</p>
        <p><related-object link-type="booklink" source-id="gene" document-id="ebd" document-type="chapter"><bold>Dystrophic EB</bold></related-object>
<bold>(DEB).</bold> The blister forms below the basement membrane, in the superficial dermis. The basement membrane is attached to the blister roof, resulting in scarring when blisters heal. Both heterozygous and biallelic pathogenic variants in <italic toggle="yes">COL7A1</italic>, the gene encoding type VII collagen, have been associated with DEB.</p>
        <p><bold>The designation Bart syndrome</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/132000">132000</ext-link>) is not used in the current classification of EB. Bart characterized a kindred with congenital absence of the skin on the lower legs and feet, non-scarring blistering of the skin and oral mucosa, and nail abnormalities. Genetic studies of the original kindred identified heterozygous pathogenic variants in <italic toggle="yes">COL7A1</italic> [<xref ref-type="bibr" rid="ebs.REF.christiano.1996.1340">Christiano et al 1996</xref>], and some consider Bart syndrome to be most often, but not exclusively, a manifestation of dominant DEB. However, congenital absence of skin can be seen in all forms in EB and may not be a distinguishing feature of any particular form of EB.</p>
      </sec>
      <sec id="ebs.Management">
        <title>Management</title>
        <sec id="ebs.Evaluations_Following_Initial_Diagno">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with epidermolysis bullosa simplex (EBS), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Consultation with a dermatologist to evaluate the sites of blister formation, including oral mucosa</p>
            </list-item>
            <list-item>
              <p>Consultation with a clinical geneticist and/or genetic counselor</p>
            </list-item>
          </list>
        </sec>
        <sec id="ebs.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Supportive care to protect the skin from blistering, appropriate dressings that will not further damage the skin and will promote healing of open wounds, and prevention and treatment of secondary infection are the mainstays of EB treatment.</p>
          <p>Encourage children to tailor their activities to minimize trauma to the skin while participating as much as possible in age-appropriate play.</p>
          <p>Lance and drain new blisters to prevent further spread from fluid pressure.</p>
          <p>Dressings usually involve three layers:</p>
          <list list-type="bullet">
            <list-item>
              <p>A primary nonadherent dressing that will adhere to the top layers of the epidermis must be used. There is wide variability in tolerance to different primary layers; some individuals with EBS can use ordinary bandages. Some dressings are impregnated with an emollient such as petrolatum or topical antiseptic (e.g., Vaseline<sup>&#x000ae;</sup> Gauze, Adaptic<sup>&#x000ae;</sup>, Xeroform). Nonstick products (e.g., Telfa or N-Terface<sup>&#x000ae;</sup>) or silicone-based products without adhesive (e.g., Mepitel<sup>&#x000ae;</sup> or Mepilex<sup>&#x000ae;</sup>) are also popular.</p>
            </list-item>
            <list-item>
              <p>A secondary layer absorbs drainage, provides stability for the primary layer, and adds padding to allow more activity. Foam dressings and/or rolls of gauze (e.g., Kerlix<sup>&#x000ae;</sup>) are commonly used.</p>
            </list-item>
            <list-item>
              <p>A tertiary layer, usually with some elastic properties, ensures the integrity of the dressing (e.g., Coban&#x02122; or elasticized tube gauze of varying diameters, such as BandNet<sup>&#x000ae;</sup>).</p>
            </list-item>
          </list>
          <p>Note: Many individuals with EBS, in contrast to those with junctional EB and dystrophic EB, find that excessive bandaging may actually lead to more blistering, presumably as a result of increased heat and sweating. Such individuals may benefit from dusting the affected areas with corn starch to help absorb moisture and reduce friction on the skin, followed by a simple (i.e., one-layer) dressing.</p>
        </sec>
        <sec id="ebs.Prevention_of_Primary_Manifestations">
          <title>Prevention of Primary Manifestations</title>
          <p>In the following studies, small sample sizes limit the statistical validity and generalizability of the results; however, given the lack of effective treatments for EBS, these potentially helpful treatments should be considered on a case-by-case basis:</p>
          <list list-type="bullet">
            <list-item>
              <p>20% aluminum chloride applied to palms and soles can reduce blister formation in some individuals with EBS, presumably by decreasing sweating.</p>
            </list-item>
            <list-item>
              <p>A case report [<xref ref-type="bibr" rid="ebs.REF.abitbol.2009.13">Abitbol &#x00026; Zhou 2009</xref>] and small study [<xref ref-type="bibr" rid="ebs.REF.swartling.2010.1072">Swartling et al 2010</xref>] suggest that injection of botulinum toxin into the feet is effective in reducing blistering and associated pain. The mechanism of action is unclear, but likely relates to reduction of sweating and subsequent maceration of the skin.</p>
            </list-item>
            <list-item>
              <p>In one study of a limited number of individuals with EBS-gen sev, cyproheptadine (Periactin<sup>&#x000ae;</sup>) reduced blistering. This may result from the anti-pruritic effect of the medication, but the true mechanism is not clear [<xref ref-type="bibr" rid="ebs.REF.neufeldkaiser.1997.251">Neufeld-Kaiser &#x00026; Sybert 1997</xref>].</p>
            </list-item>
            <list-item>
              <p>In another study, tetracycline reduced blister counts in two thirds of persons with EBS-loc [<xref ref-type="bibr" rid="ebs.REF.weiner.2004.613">Weiner et al 2004</xref>]. A recent study evaluated three months of oral erythromycin therapy in six children ages one to eight years with EBS-gen sev, and showed the medication was well tolerated and improved blistering in three children [<xref ref-type="bibr" rid="ebs.REF.chiaverini.2015.563">Chiaverini et al 2015</xref>]. An anti-inflammatory mechanism, rather an anti-microbial mechanism, is proposed for the effect of antibiotics in the treatment of EBS.</p>
            </list-item>
          </list>
          <p><bold>Other.</bold> Use of keratolytics and softening agents such as urea for palmar plantar hyperkeratosis has some benefit in preventing tissue thickening and cracking. In addition, soaking the hands and feet in salt water helps soften hyperkeratosis and ease debridement of the thick skin.</p>
        </sec>
        <sec id="ebs.Prevention_of_Secondary_Complication">
          <title>Prevention of Secondary Complications</title>
          <p>Infection is the most common secondary complication. Surveillance for wound infection is important and treatment with topical and/or systemic antibiotics or silver-impregnated dressings or gels can be helpful.</p>
          <p>Additional nutritional support may be required for failure to thrive in infants and children with EBS-gen sev or EBS-gen intermed who have more severe involvement. Infants with significant oral disease may develop an aversion to eating by mouth, even after oral disease improves. The involvement of a feeding therapist in these cases is suggested.</p>
          <p>Management of fluid and electrolyte problems is critical, as they can be significant and even life-threatening in the neonatal period and in infants with widespread disease.</p>
          <p>Some children have delays or difficulty walking because of blistering and hyperkeratosis, especially in EBS-gen sev. Appropriate footwear and physical therapy are essential to preserve ambulation.</p>
        </sec>
        <sec id="ebs.Surveillance">
          <title>Surveillance</title>
          <p>Surveillance for infection and proper wound healing is indicated.</p>
        </sec>
        <sec id="ebs.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Excessive heat may exacerbate blistering and infection in EBS.</p>
          <p>Poorly fitting or coarse-textured clothing and footwear can cause trauma and should be avoided.</p>
          <p>Avoiding activities that traumatize the skin (e.g., hiking, mountain biking, contact sports) can reduce skin damage, but affected individuals who are determined to find ways to participate in these endeavors should be encouraged.</p>
          <p>Many individuals with EBS cannot use ordinary medical tape or Band-Aids<sup>&#x000ae;</sup>.</p>
        </sec>
        <sec id="ebs.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="ebs.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="ebs.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>If a fetus is known to be affected with any form of EB, caesarean delivery may reduce the trauma to the skin during delivery.</p>
        </sec>
        <sec id="ebs.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Proposed approaches to gene therapy for EBS include use of ribozymes, addition of other functional proteins [<xref ref-type="bibr" rid="ebs.REF.dalessandro.2004.1290">D'Alessandro et al 2004</xref>], induction of a compensating pathogenic variant [<xref ref-type="bibr" rid="ebs.REF.smith.2004a.73">Smith et al 2004a</xref>], and use of pathogenic variant-specific siRNAs [<xref ref-type="bibr" rid="ebs.REF.atkinson.2011.2079">Atkinson et al 2011</xref>]; no clinical trials have been carried out. The inducible mouse model for EBS should facilitate the development of these therapeutic approaches [<xref ref-type="bibr" rid="ebs.REF.arin.2004.160">Arin &#x00026; Roop 2004</xref>].</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
        <sec id="ebs.Other">
          <title>Other</title>
          <p>The use of corticosteroids and vitamin E in treating EBS has been reported anecdotally; no rigorous clinical trials have been undertaken.</p>
        </sec>
      </sec>
      <sec id="ebs.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="ebs.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Epidermolysis bullosa simplex (EBS) caused by pathogenic variants in <italic toggle="yes">EXPH5</italic> or <italic toggle="yes">TGM5</italic> is inherited in an autosomal recessive manner. EBS caused by pathogenic variants in <italic toggle="yes">KRT5</italic> or <italic toggle="yes">KRT14</italic> is usually inherited in an autosomal dominant manner; in rare cases it can be inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="ebs.Risk_to_Family_Members__Autosomal_Re">
          <title>Risk to Family Members &#x02014; Autosomal Recessive Inheritance</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes for an EBS-related pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>Typically, heterozygous parents of a child with autosomal recessive EBS are unaffected; however, phenotypically similar ectodermal dysplasia syndromes (see <xref ref-type="sec" rid="ebs.Genetically_Related_Allelic_Disorder">Genetically Related Disorders</xref>) can be caused by a heterozygous pathogenic variant associated with autosomal recessive EBS [<xref ref-type="bibr" rid="ebs.REF.betz.2006.510">Betz et al 2006</xref>, <xref ref-type="bibr" rid="ebs.REF.lugassy.2006.724">Lugassy et al 2006</xref>, <xref ref-type="bibr" rid="ebs.REF.liao.2007.298">Liao et al 2007</xref>, <xref ref-type="bibr" rid="ebs.REF.sprecher.2007.572">Sprecher et al 2007</xref>].</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being heterozygous and possibly being affected with the same disorder, and a 25% chance of being unaffected and not heterozygous.</p>
            </list-item>
            <list-item>
              <p>Typically, heterozygous sibs of a proband with autosomal recessive EBS are unaffected; however, phenotypically similar ectodermal dysplasia syndromes (see <xref ref-type="sec" rid="ebs.Genetically_Related_Allelic_Disorder">Genetically Related Disorders</xref>) can be caused by heterozygosity for pathogenic variants associated with autosomal recessive EBS [<xref ref-type="bibr" rid="ebs.REF.betz.2006.510">Betz et al 2006</xref>, <xref ref-type="bibr" rid="ebs.REF.lugassy.2006.724">Lugassy et al 2006</xref>, <xref ref-type="bibr" rid="ebs.REF.liao.2007.298">Liao et al 2007</xref>, <xref ref-type="bibr" rid="ebs.REF.sprecher.2007.572">Sprecher et al 2007</xref>].</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The offspring of an individual with autosomal recessive EBS are obligate heterozygotes for an EBS-related pathogenic variant.</p>
          <p><bold>Other family members.</bold> Each sib of a proband's parents is at a 50% risk of being having an EBS-related pathogenic variant.</p>
          <p><bold>Heterozygote (carrier) detection.</bold> Carrier testing for at-risk relatives requires prior identification of the EBS-related pathogenic variants in the family.</p>
        </sec>
        <sec id="ebs.Risk_to_Family_Members__Autosomal_Do">
          <title>Risk to Family Members &#x02014; Autosomal Dominant Inheritance</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Many individuals diagnosed with <italic toggle="yes">KRT5</italic> or <italic toggle="yes">KRT14</italic>-related EBS have an affected parent from whom they inherited a pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>EBS can also be caused by a <italic toggle="yes">de novo KRT5</italic> or <italic toggle="yes">KRT14</italic> pathogenic variant. Individuals with severe forms of autosomal dominant EBS usually have a <italic toggle="yes">de novo</italic> pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>If the pathogenic variant found in the proband cannot be detected in leukocyte DNA of either parent, possible explanations include a <italic toggle="yes">de novo</italic> pathogenic variant in the proband or germline mosaicism in a parent. Germline mosaicism has been reported in the mother of a proband with EBS [<xref ref-type="bibr" rid="ebs.REF.nagaowatanabe.2004.236">Nagao-Watanabe et al 2004</xref>].</p>
            </list-item>
            <list-item>
              <p>Recommendations for the evaluation of parents of a proband with an apparent <italic toggle="yes">de novo</italic> pathogenic variant include taking a personal history and performing a physical examination if the history is suggestive.</p>
            </list-item>
            <list-item>
              <p>Evaluation of parents may determine that one is affected but has escaped previous diagnosis because of failure by health care professionals to recognize the syndrome and/or a milder phenotypic presentation. Many families include individuals with a history of "blistering" but are unaware that these individuals have EBS. Therefore, an apparently negative family history cannot be confirmed unless appropriate clinical evaluation and/or molecular genetic testing has been performed on the parents of the proband.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the sibs of the proband depends on the genetic status of the proband&#x02019;s parents.</p>
            </list-item>
            <list-item>
              <p>If a parent of the proband is affected, the risk to the sibs is 50%.</p>
            </list-item>
            <list-item>
              <p>When the parents are clinically unaffected, the risk to the sibs of a proband appears to be low.</p>
            </list-item>
            <list-item>
              <p>If the <italic toggle="yes">KRT5</italic> or <italic toggle="yes">KRT14</italic> pathogenic variant found in the proband cannot be detected in the leukocyte DNA of either parent, the risk to sibs is slightly greater than that of the general population because of the possibility of germline mosaicism [<xref ref-type="bibr" rid="ebs.REF.nagaowatanabe.2004.236">Nagao-Watanabe et al 2004</xref>].</p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Each child of an individual with EBS has a 50% chance of inheriting the <italic toggle="yes">KRT5</italic> or <italic toggle="yes">KRT14</italic> pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>In the rare situation in which both parents have an autosomal dominant pathogenic variant (e.g., in consanguineous unions), each child has a 75% chance of having at least one pathogenic variant.</p>
            </list-item>
          </list>
          <p><bold>Other family members.</bold> The risk to other family members depends on the status of the proband's parents: if a parent is affected, his or her family members are at risk.</p>
        </sec>
        <sec id="ebs.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>
            <bold>Establishing the mode of inheritance</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Mode of inheritance is usually established by pedigree analysis. Autosomal recessive inheritance is suspected in pedigrees showing consanguinity and affected sibs born to unaffected parents.</p>
            </list-item>
            <list-item>
              <p>Skin biopsy findings can also be helpful in distinguishing autosomal recessive and autosomal dominant forms of EBS (see <xref ref-type="sec" rid="ebs.Establishing_the_Diagnosis">Establishing the Diagnosis</xref>, <bold>Skin biopsy</bold>).</p>
            </list-item>
          </list>
          <p>Note: In families with an apparent <italic toggle="yes">de novo</italic> pathogenic variant, non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) and undisclosed adoption could also be explored.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk of being heterozygous for an EBS-related pathogenic variant.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="ebs.Prenatal_Testing_and_Preimplantation">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the EBS-related pathogenic variant(s) have been identified in an affected family member, prenatal testing for a pregnancy at increased and preimplantation genetic diagnosis are possible options.</p>
        </sec>
      </sec>
      <sec id="ebs.Resources">
        <title>Resources</title>
      </sec>
      <sec id="ebs.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="ebs.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p><italic toggle="yes">KRT5</italic> and <italic toggle="yes">KRT14</italic> are expressed in the basal keratinocytes of the epidermis (the inner-most layer), where their protein products form heterodimeric molecules that assemble into the intracellular keratin intermediate filament network. This network is linked directly to the hemidesmosomes that anchor the keratinocytes to the basal lamina and to the desmosomes, leading to strong attachment of the keratinocytes to one another. These associations along with the network itself supply stability and resistance to stress, enabling the keratinocytes to maintain their structural integrity during minor trauma. <italic toggle="yes">TGM5</italic> encodes the transglutaminase 5 enzyme, which is strongly expressed in the epidermal granular cells, where it crosslinks a variety of structural proteins in the terminal differentiation of the epidermis to form the cornified cell envelope (the outer-most layer). <italic toggle="yes">EXPH5</italic> encodes a RAB27b GTPase effector protein, exophilin-5, which is not a structural protein, but rather plays a role in cell membrane trafficking and vesicle formation.</p>
          <p>Autosomal dominant (heterozygous) pathogenic variants in <italic toggle="yes">KRT5</italic> and <italic toggle="yes">KRT14</italic> cause clinical features by acting in a dominant-negative manner. Dominant-negative missense variants predominate and often affect the ability of the keratin to associate with its keratin partner, its secondary structure, and its ability to form the intracellular network. Intrafamilial phenotypic variability exists, suggesting that other factors can affect the resistance of the cells to friction [<xref ref-type="bibr" rid="ebs.REF.rugg.2004.4">Rugg &#x00026; Leigh 2004</xref>, <xref ref-type="bibr" rid="ebs.REF.smith.2004a.73">Smith et al 2004a</xref>, <xref ref-type="bibr" rid="ebs.REF.werner.2004.990">Werner et al 2004</xref>]. In two different highly consanguineous families with autosomal dominant EBS, offspring homozygous for a pathogenic missense variant have been reported.</p>
          <p>Autosomal recessive (biallelic) <italic toggle="yes">EXPH5</italic> and <italic toggle="yes">KRT14</italic>, pathogenic variants are those that cause symptoms only in homozygotes or compound heterozygotes. In the few reported cases of autosomal recessive EBS caused by <italic toggle="yes">KRT14</italic> and <italic toggle="yes">EXPH5</italic> variants, the pathogenic variants are usually functionally null alleles that produce no gene product. Autosomal recessive pathogenic variants in <italic toggle="yes">TGM5</italic> are often missense variants that affect the crosslinking capabilities of the enzyme. Typically, heterozygotes are unaffected because 50% of the normal keratin product is adequate to stabilize the skin, although reports of related autosomal dominant disorders caused by null alleles in <italic toggle="yes">KRT5</italic> and <italic toggle="yes">KRT14</italic> resulting in haploinsufficiency have also been reported [<xref ref-type="bibr" rid="ebs.REF.betz.2006.510">Betz et al 2006</xref>, <xref ref-type="bibr" rid="ebs.REF.lugassy.2006.724">Lugassy et al 2006</xref>, <xref ref-type="bibr" rid="ebs.REF.liao.2007.298">Liao et al 2007</xref>, <xref ref-type="bibr" rid="ebs.REF.sprecher.2007.572">Sprecher et al 2007</xref>] (see <xref ref-type="sec" rid="ebs.Genetically_Related_Allelic_Disorder">Genetically Related Disorders</xref>).</p>
          <sec id="ebs.EXPH5">
            <title>
              <italic toggle="yes">EXPH5</italic>
            </title>
            <p><bold>Gene structure.</bold>
<italic toggle="yes">EXPH5</italic> encodes up to 11 known splicing variants; the v1 variant, encoding the longest mRNA at 10208 bp (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/NM_015065">NM_015065</ext-link>), comprises six exons. (For more information, see <related-object source-id="gene" document-id="ebs" object-id="ebs.molgen.TA">Table A</related-object>.)</p>
            <p><bold>Pathogenic variants.</bold> Fewer than ten pathogenic variants have been described throughout the gene; to date, all have been null variants. All known affected individuals that have been described are from the Middle East, where consanguinity is common.</p>
            <p><bold>Normal gene product.</bold>
<italic toggle="yes">EXPH5</italic> encodes the 1983-amino acid protein exophilin-5, a Rab27 effector protein. Rab proteins are members of the large Ras superfamily of monomeric G proteins. Rab GTPases regulate many key steps of cell membrane traffic, including vesicle formation, vesicle movement along actin and tubulin networks, and membrane fusion. Rab GTPases control trafficking in endocytic and secretory pathways by recruiting proteins onto membrane surfaces that are involved in cargo collection, organelle motility, or vesicle docking at membranes. Exophilin-5, is involved in intracellular protein transport and exosome secretion [<xref ref-type="bibr" rid="ebs.REF.ostrowski.2010.19">Ostrowski et al 2010</xref>].</p>
            <p><bold>Abnormal gene product.</bold> Electron microscopy of skin biopsies from affected individuals with truncating <italic toggle="yes">EXPH5</italic> variants shows a disruption of the keratin filament architecture and more cortically disturbed F actin compared to controls. How the abnormal gene product causes this disruption is unknown.</p>
          </sec>
          <sec id="ebs.KRT5">
            <title>
              <italic toggle="yes">KRT5</italic>
            </title>
            <p><bold>Gene structure.</bold> The cDNA comprises 2,164 bp in eight exons. Genomic length is estimated at approximately 6 kb. (For more information, see <related-object source-id="gene" document-id="ebs" object-id="ebs.molgen.TA">Table A</related-object>.)</p>
            <p><bold>Pathogenic variants.</bold> Pathogenic variants in the nonhelical linker segments (L1 and L2) and in the 1A segment of the rod domain are associated with EBS-loc. Pathogenic variants in the 1A or 2B segments of the rod domain of <italic toggle="yes">KRT5</italic> and <italic toggle="yes">KRT14</italic> are common for EBS-gen intermed. Pathogenic variants in the beginning of the 1A segment or the end of the 2B segment of the rod domain of <italic toggle="yes">KRT5</italic> and <italic toggle="yes">KRT14</italic> are typical in EBS-gen sev.</p>
            <p>The <italic toggle="yes">KRT5</italic> recurrent pathogenic missense variant p.Glu477Lys, along with the common <xref ref-type="sec" rid="ebs.KRT14"><italic toggle="yes">KRT14</italic> recurrent pathogenic variants</xref> are thought to account for approximately 70% of cases of EBS-gen sev [<xref ref-type="bibr" rid="ebs.REF.stephens.1997.349">Stephens et al 1997</xref>, <xref ref-type="bibr" rid="ebs.REF.pfendner.2005b.239">Pfendner et al 2005b</xref>].</p>
            <p>The <italic toggle="yes">KRT5</italic> pathogenic missense variant p.Pro25Leu [<xref ref-type="bibr" rid="ebs.REF.moog.1999.376">Moog et al 1999</xref>] accounts for 90%-95% of identified pathogenic variants in individuals with EBS-MP. The <italic toggle="yes">KRT5</italic> pathogenic variant c.1649delG is also responsible for a mottled pigmentation phenotype [<xref ref-type="bibr" rid="ebs.REF.horiguchi.2005.83">Horiguchi et al 2005</xref>].</p>
            <p>Although a formal possibility, homozygosity for null <italic toggle="yes">KRT5</italic> alleles has not been reported. Whether this genotype results in autosomal recessive EBS-gen intermed is unknown. An autosomal recessive pathogenic missense variant has been described [<xref ref-type="bibr" rid="ebs.REF.indelman.2005.272">Indelman et al 2005</xref>].</p>
            <p>In one family, an individual with biallelic <italic toggle="yes">KRT5</italic> pathogenic variants had clinical features indistinguishable from those associated with heterozygous <italic toggle="yes">KRT5</italic> pathogenic variants [<xref ref-type="bibr" rid="ebs.REF.stephens.1995.577">Stephens et al 1995</xref>).</p>
            <table-wrap id="ebs.T.pathogenic_krt5_variants_discussed" orientation="portrait" position="anchor">
              <label>Table 5. </label>
              <caption>
                <p>Pathogenic <italic toggle="yes">KRT5</italic> Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_ebs.T.pathogenic_krt5_variants_discussed_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                    <th id="hd_h_ebs.T.pathogenic_krt5_variants_discussed_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                    <th id="hd_h_ebs.T.pathogenic_krt5_variants_discussed_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_ebs.T.pathogenic_krt5_variants_discussed_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.74C&#x0003e;T</td>
                    <td headers="hd_h_ebs.T.pathogenic_krt5_variants_discussed_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Pro25Leu<break/>(Pro24Leu)</td>
                    <td headers="hd_h_ebs.T.pathogenic_krt5_variants_discussed_1_1_1_3" rowspan="3" valign="middle" align="left" colspan="1">
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&#x00026;id=119395753">NM_000424.3</ext-link>
                      <break/>
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&#x00026;id=119395754">NP_000415.2</ext-link>
                    </td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ebs.T.pathogenic_krt5_variants_discussed_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1649delG</td>
                    <td headers="hd_h_ebs.T.pathogenic_krt5_variants_discussed_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly550AlafsTer77&#x000a0;<sup>2</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ebs.T.pathogenic_krt5_variants_discussed_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1429G&#x0003e;A</td>
                    <td headers="hd_h_ebs.T.pathogenic_krt5_variants_discussed_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Glu477Lys</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
                </fn>
                <fn>
                  <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
                </fn>
                <fn id="ebs.TF.5.1">
                  <label>1. </label>
                  <p>Variant designation that does not conform to current naming conventions</p>
                </fn>
                <fn id="ebs.TF.5.2">
                  <label>2. </label>
                  <p>&#x02018;Ter&#x02019; indicates translation extended downstream of the normal translation termination codon.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p><bold>Normal gene product.</bold> KRT5 (keratin, type II cytoskeletal 5) is a protein of 590 amino acids.</p>
            <p><bold>Abnormal gene product.</bold> The mechanism of disease is dependent on the variant, but often gain-of-function variants result in protein that prevents proper association with the protein partner (krt5-krt14) and assembly of those associated dimers into bundles and fibers.</p>
          </sec>
          <sec id="ebs.KRT14">
            <title>
              <italic toggle="yes">KRT14</italic>
            </title>
            <p><bold>Gene structure.</bold> The cDNA comprises 1,377 bp in eight exons. Genomic length is approximately 4.5 kb. (For more information, see <related-object source-id="gene" document-id="ebs" object-id="ebs.molgen.TA">Table A</related-object>.)</p>
            <p><bold>Pathogenic variants.</bold> Pathogenic variants in the nonhelical linker segments (L1 and L2) and in the 1A segment of the rod domain are associated with EBS-loc. Pathogenic variants in the 1A or 2B segments of the rod domain are typical for EBS-gen intermed.</p>
            <p>The <xref ref-type="sec" rid="ebs.KRT5"><italic toggle="yes">KRT5</italic></xref> recurrent pathogenic missense variant along with the common <italic toggle="yes">KRT14</italic> recurrent pathogenic variants p.Arg125Cys, p.Arg125His, and p.Asn123Ser are thought to account for approximately 70% of cases of EBS-gen sev [<xref ref-type="bibr" rid="ebs.REF.stephens.1997.349">Stephens et al 1997</xref>, <xref ref-type="bibr" rid="ebs.REF.pfendner.2005b.239">Pfendner et al 2005b</xref>]. The p.Arg125Cys and p.Arg125His hotspot pathogenic variants alone have been identified as causal in approximately 50% of individuals with EBS-gen sev (see <xref ref-type="table" rid="ebs.T.pathogenic_krt14_variants_discusse">Table 6</xref>).</p>
            <p>In rare consanguineous families, biallelic pathogenic null <italic toggle="yes">KRT14</italic> variants are associated with autosomal recessive inheritance of EBS-gen intermed.</p>
            <p>The <italic toggle="yes">KRT14</italic> pathogenic variant p.Met119Thr (<xref ref-type="table" rid="ebs.T.pathogenic_krt14_variants_discusse">Table 6</xref>) was recently described as associated with the EBS-MP phenotype [<xref ref-type="bibr" rid="ebs.REF.harel.2006.1654">Harel et al 2006</xref>].</p>
            <p>An individual with biallelic <italic toggle="yes">KRT14</italic> pathogenic variants was more severely affected than relatives who had heterozygous <italic toggle="yes">KRT14</italic> pathogenic variants [<xref ref-type="bibr" rid="ebs.REF.hu.1997.360">Hu et al 1997</xref>].</p>
            <table-wrap id="ebs.T.pathogenic_krt14_variants_discusse" orientation="portrait" position="anchor">
              <label>Table 6. </label>
              <caption>
                <p>Pathogenic <italic toggle="yes">KRT14</italic> Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_ebs.T.pathogenic_krt14_variants_discusse_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                    <th id="hd_h_ebs.T.pathogenic_krt14_variants_discusse_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                    <th id="hd_h_ebs.T.pathogenic_krt14_variants_discusse_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_ebs.T.pathogenic_krt14_variants_discusse_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.256T&#x0003e;C</td>
                    <td headers="hd_h_ebs.T.pathogenic_krt14_variants_discusse_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Met119Thr</td>
                    <td headers="hd_h_ebs.T.pathogenic_krt14_variants_discusse_1_1_1_3" rowspan="4" valign="middle" align="left" colspan="1">
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000526">NM_000526.4</ext-link>
                      <break/>
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&#x00026;id=15431310">NP_000517.2</ext-link>
                    </td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ebs.T.pathogenic_krt14_variants_discusse_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.368A&#x0003e;G</td>
                    <td headers="hd_h_ebs.T.pathogenic_krt14_variants_discusse_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Asn123Ser</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ebs.T.pathogenic_krt14_variants_discusse_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.373C&#x0003e;T</td>
                    <td headers="hd_h_ebs.T.pathogenic_krt14_variants_discusse_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg125Cys</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ebs.T.pathogenic_krt14_variants_discusse_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.374G&#x0003e;A</td>
                    <td headers="hd_h_ebs.T.pathogenic_krt14_variants_discusse_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg125His</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
                </fn>
                <fn>
                  <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p><bold>Normal gene product.</bold> KRT14 (keratin, type I, cytoskeletal 14) is a protein of 472 amino acids.</p>
            <p><bold>Abnormal gene product.</bold> Pathogenic missense variants give rise to abnormal gene products that may not assemble correctly into functional keratin intermediate filaments. The type and position of the amino acid change determines the degree of compromise and thus the severity of the condition. Pathogenic <italic toggle="yes">KRT14</italic> null variants may give rise to a less severe phenotype than certain pathogenic missense variants [<xref ref-type="bibr" rid="ebs.REF.s_rensen.2003.472">S&#x000f8;rensen et al 2003</xref>, <xref ref-type="bibr" rid="ebs.REF.smith.2004b.1043">Smith et al 2004b</xref>].</p>
          </sec>
          <sec id="ebs.TGM5">
            <title>
              <italic toggle="yes">TGM5</italic>
            </title>
            <p><bold>Gene structure.</bold>
<italic toggle="yes">TGM5</italic> encodes a 9411-bp cDNA with 13 exons and two major alternately spliced transcripts; the v2 form omits exon11. (For more information, see <related-object source-id="gene" document-id="ebs" object-id="ebs.molgen.TA">Table A</related-object>.)</p>
            <p><bold>Benign variants.</bold> The p.Thr109Met variant has been shown to be benign and often segregates with the p.Gly113Cys pathogenic variant.</p>
            <p><bold>Pathogenic variants.</bold> A common founder variant, p.Gly113Cys has been found in the European population. TGM5 is a transglutaminase involved in crosslinking of the cornified epithelium; the p.Gly113Cys pathogenic variant (common in persons of northern European background) is found in the catalytic domain and abolishes crosslinking activity by TGM5 [<xref ref-type="bibr" rid="ebs.REF.szczecinska.2014.1206">Szczecinska et al 2014</xref>].</p>
            <table-wrap id="ebs.T.tgm5_variants_discussed_in_this_ge" orientation="portrait" position="anchor">
              <label>Table 7. </label>
              <caption>
                <p><italic toggle="yes">TGM5</italic> Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_ebs.T.tgm5_variants_discussed_in_this_ge_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Classification</th>
                    <th id="hd_h_ebs.T.tgm5_variants_discussed_in_this_ge_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                    <th id="hd_h_ebs.T.tgm5_variants_discussed_in_this_ge_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                    <th id="hd_h_ebs.T.tgm5_variants_discussed_in_this_ge_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_ebs.T.tgm5_variants_discussed_in_this_ge_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                      <bold>Benign</bold>
                    </td>
                    <td headers="hd_h_ebs.T.tgm5_variants_discussed_in_this_ge_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.326C&#x0003e;T</td>
                    <td headers="hd_h_ebs.T.tgm5_variants_discussed_in_this_ge_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Thr109Met</td>
                    <td headers="hd_h_ebs.T.tgm5_variants_discussed_in_this_ge_1_1_1_4" rowspan="2" valign="middle" align="left" colspan="1">
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/NM_201631.1">NM_201631.1</ext-link>
                    </td>
                  </tr>
                  <tr>
                    <td headers="hd_h_ebs.T.tgm5_variants_discussed_in_this_ge_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                      <bold>Pathogenic</bold>
                    </td>
                    <td headers="hd_h_ebs.T.tgm5_variants_discussed_in_this_ge_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.337G&#x0003e;T</td>
                    <td headers="hd_h_ebs.T.tgm5_variants_discussed_in_this_ge_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gly113Cys</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
                </fn>
                <fn>
                  <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p><bold>Normal gene product.</bold> The normal TGM5v1 (TGX) gene product has 720 amino acids including catalytic domain. TGM5 is a transglutaminase involved in crosslinking of the cornified epithelium (the outer-most layer of the epidermis) which is particularly important in the terminal differentiation of the epidermis</p>
            <p><bold>Abnormal gene product.</bold> Null variants and variants that abolish the enzymatic activity or crosslinking function cause reduced crosslinking and altered stability and reduced barrier function of the cornified epithelium.</p>
          </sec>
        </sec>
      </sec>
      <sec id="ebs.References">
        <title>References</title>
        <sec id="ebs.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="ebs.Literature_Cited.reflist0">
            <ref id="ebs.REF.abitbol.2009.13">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Abitbol</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>LH</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Treatment of epidermolysis bullosa simplex, Weber-Cockayne type, with botulinum toxin type A.</article-title>
                <source>Arch Dermatol.</source>
                <volume>145</volume>
                <fpage>13</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">19153338</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.abu_sad.2006.777">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Abu Sa'd</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Indelman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pfendner</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Falik-Zaccai</surname>
                    <given-names>TC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mizrachi-Koren</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shalev</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ben Amitai</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raas-Rothshild</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adir-Shani</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Borochowitz</surname>
                    <given-names>ZU</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gershoni-Baruch</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Khayat</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Landau</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richard</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergman</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uitto</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kanaan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sprecher</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Molecular epidemiology of hereditary epidermolysis bullosa in a Middle Eastern population.</article-title>
                <source>J Invest Dermatol.</source>
                <volume>126</volume>
                <fpage>777</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">16439963</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.arin.2010.1365">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Arin</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grimberg</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schumann</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Almeida</surname>
                    <given-names>H</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Chang</surname>
                    <given-names>YR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tadini</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kohlhase</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krieg</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruckner-Tuderman</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Has</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Identification of novel and known KRT5 and KRT14 mutations in 53 patients with epidermolysis bullosa simplex: correlation between genotype and phenotype.</article-title>
                <source>Br J Dermatol.</source>
                <volume>162</volume>
                <fpage>1365</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">20199538</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.arin.2004.160">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Arin</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roop</surname>
                    <given-names>DR</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Inducible mouse models for inherited skin diseases: implications for skin gene therapy.</article-title>
                <source>Cells Tissues Organs</source>
                <volume>177</volume>
                <fpage>160</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15388990</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.atkinson.2011.2079">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Atkinson</surname>
                    <given-names>SD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McGilligan</surname>
                    <given-names>VE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liao</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Szeverenyi</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moore</surname>
                    <given-names>CB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McLean</surname>
                    <given-names>WH</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Development of allele-specific therapeutic siRNA for keratin 5 mutations in epidermolysis bullosa simplex.</article-title>
                <source>J Invest Dermatol.</source>
                <volume>131</volume>
                <fpage>2079</fpage>
                <lpage>86</lpage>
                <pub-id pub-id-type="pmid">21716320</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.bergman.2007.463">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bergman</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harel</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sprecher</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Dyskeratosis as a histologic feature in epidermolysis bullosa simplex-Dowling Meara.</article-title>
                <source>J Am Acad Dermatol</source>
                <volume>57</volume>
                <fpage>463</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">17707151</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.betz.2006.510">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Betz</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Planko</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eigelshoven</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanneken</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pasternack</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bussow</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Den Bogaert</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wenzel</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Braun-Falco</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rutten</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rogers</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruzicka</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>N&#x000f6;then</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Magin</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kruse</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Loss-of-function mutations in the keratin 5 gene lead to Dowling-Degos disease.</article-title>
                <source>Am J Hum Genet.</source>
                <volume>78</volume>
                <fpage>510</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16465624</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.bolling.2014.273">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bolling</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jongbloed</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boven</surname>
                    <given-names>LG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Diercks</surname>
                    <given-names>GF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McLean</surname>
                    <given-names>WH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jonkman</surname>
                    <given-names>MF</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>Plectin mutations underlie epidermolysis bullosa simplex in 8% of patients.</article-title>
                <source>J Invest Dermatol.</source>
                <volume>134</volume>
                <fpage>273</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">23774525</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.bolling.2011.637">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bolling</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lemmink</surname>
                    <given-names>HH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jansen</surname>
                    <given-names>GH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jonkman</surname>
                    <given-names>MF</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Mutations in KRT5 and KRT14 cause epidermolysis bullosa simplex in 75% of the patients.</article-title>
                <source>Br J Dermatol.</source>
                <volume>164</volume>
                <fpage>637</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">21375516</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.bolling.2010.1388">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bolling</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Veenstra</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jonkman</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Diercks</surname>
                    <given-names>GF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Curry</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fisher</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pas</surname>
                    <given-names>HH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruckner</surname>
                    <given-names>AL</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Lethal acantholytic epidermolysis bullosa due to a novel homozygous deletion in DSP: expanding the phenotype and implications for desmoplakin function in skin and heart.</article-title>
                <source>Br J Dermatol.</source>
                <volume>162</volume>
                <fpage>1388</fpage>
                <lpage>94</lpage>
                <pub-id pub-id-type="pmid">20302578</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.charlesworth.2003.1344">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Charlesworth</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gagnoux-Palacios</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonduelle</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ortonne</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Raeve</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meneguzzi</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Identification of a lethal form of epidermolysis bullosa simplex associated with a homozygous genetic mutation in plectin.</article-title>
                <source>J Invest Dermatol</source>
                <volume>121</volume>
                <fpage>1344</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">14675180</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.chiaverini.2015.563">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chiaverini</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fontas</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vabres</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bessis</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazereeuw</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Charlesworth</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meneguzzi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacour</surname>
                    <given-names>JP</given-names>
                  </name>
                </person-group>
                <year>2015</year>
                <article-title>Oral erythromycin therapy in epidermolysis bullosa simplex generalized severe.</article-title>
                <source>Br J Dermatol.</source>
                <volume>173</volume>
                <fpage>563</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">25601422</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.christiano.1996.1340">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Christiano</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bart</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Epstein</surname>
                    <given-names>EH</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Uitto</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>1996</year>
                <article-title>Genetic basis of Bart's syndrome: a glycine substitution mutation in the type VII collagen gene.</article-title>
                <source>J Invest Dermatol.</source>
                <volume>106</volume>
                <fpage>1340</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">8752681</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.dalessandro.2004.1290">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>D'Alessandro</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morley</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ogden</surname>
                    <given-names>PH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liovic</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Porter</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lane</surname>
                    <given-names>EB</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Functional improvement of mutant keratin cells on addition of desmin: an alternative approach to gene therapy for dominant diseases.</article-title>
                <source>Gene Ther</source>
                <volume>11</volume>
                <fpage>1290</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">15215887</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.fine.1999">
              <mixed-citation publication-type="book">Fine JD, Bauer EA, McGuire J, Moshell A. <italic toggle="yes">Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances and the Findings of the National Epidermolysis Registry.</italic> Baltimore, MD: Johns Hopkins University Press; 1999.</mixed-citation>
            </ref>
            <ref id="ebs.REF.fine.2014.1103">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fine</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruckner-Tuderman</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eady</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bauer</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bauer</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Has</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heagerty</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hintner</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hovnanian</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jonkman</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leigh</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marinkovich</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martinez</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McGrath</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mellerio</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moss</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murrell</surname>
                    <given-names>DF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimizu</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uitto</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Woodley</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zambruno</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification.</article-title>
                <source>J Am Acad Dermatol.</source>
                <year>2014</year>
                <volume>70</volume>
                <fpage>1103</fpage>
                <lpage>26</lpage>
                <pub-id pub-id-type="pmid">24690439</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.fine.2008.931">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fine</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eady</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bauer</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bauer</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruckner-Tuderman</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heagerty</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hintner</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hovnanian</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jonkman</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leigh</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McGrath</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mellerio</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murrell</surname>
                    <given-names>DF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimizu</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uitto</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vahlquist</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Woodley</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zambruno</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB.</article-title>
                <source>J Am Acad Dermatol.</source>
                <volume>58</volume>
                <fpage>931</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">18374450</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.groves.2010.1551">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Groves</surname>
                    <given-names>RW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dopping-Hepenstal</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Markus</surname>
                    <given-names>HS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lovell</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozoemena</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lai-Cheong</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gawler</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Owaribe</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hashimoto</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mellerio</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mee</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McGrath</surname>
                    <given-names>JA</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>A homozygous nonsense mutation within the dystonin gene coding for the coiled-coil domain of the epithelial isoform of BPAG1 underlies a new subtype of autosomal recessive epidermolysis bullosa simplex.</article-title>
                <source>J Invest Dermatol.</source>
                <volume>130</volume>
                <fpage>1551</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">20164846</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.hamada.2004.609">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hamada</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ishii</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawano</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inoue</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yasumoto</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hashimoto</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>The P25L mutation in the KRT5 gene in a Japanese family with epidermolysis bullosa simplex with mottled pigmentation.</article-title>
                <source>Br J Dermatol</source>
                <volume>150</volume>
                <fpage>609</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">15030360</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.hanneken.2010.197">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hanneken</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>R&#x000fc;tten</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pasternack</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eigelshoven</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>El Shabrawi-Caelen</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wenzel</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Braun-Falco</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruzicka</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>N&#x000f6;then</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kruse</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Betz</surname>
                    <given-names>RC</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Systematic mutation screening of KRT5 supports the hypothesis that Galli-Galli disease is a variant of Dowling-Degos disease.</article-title>
                <source>Br J Dermatol.</source>
                <volume>163</volume>
                <fpage>197</fpage>
                <lpage>200</lpage>
                <pub-id pub-id-type="pmid">20222933</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.harel.2006.1654">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Harel</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergman</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Indelman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sprecher</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Epidermolysis bullosa simplex with mottled pigmentation resulting from a recurrent mutation in KRT14.</article-title>
                <source>J Invest Dermatol</source>
                <volume>126</volume>
                <fpage>1654</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16601668</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.hobbs.2010.2680">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hobbs</surname>
                    <given-names>RP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Han</surname>
                    <given-names>SY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Zwaag</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bolling</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jongbloed</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jonkman</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Getsios</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paller</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Green</surname>
                    <given-names>KJ</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Insights from a desmoplakin mutation identified in lethal acantholytic epidermolysis bullosa.</article-title>
                <source>J Invest Dermatol.</source>
                <volume>130</volume>
                <fpage>2680</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">20613772</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.horiguchi.2005.83">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Horiguchi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sawamura</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mori</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakamura</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimizu</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Clinical heterogeneity of 1649delG mutation in the tail domain of keratin 5: a Japanese family with epidermolysis bullosa simplex with mottled pigmentation.</article-title>
                <source>J Invest Dermatol</source>
                <volume>125</volume>
                <fpage>83</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">15982306</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.horn.1997.560">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Horn</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Priestley</surname>
                    <given-names>GC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eady</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tidman</surname>
                    <given-names>MJ</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>The prevalence of epidermolysis bullosa in Scotland.</article-title>
                <source>Br J Dermatol</source>
                <volume>136</volume>
                <fpage>560</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">9155958</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.hu.1997.360">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hu</surname>
                    <given-names>ZL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martins</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonifas</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Epstein</surname>
                    <given-names>EH</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Partial dominance of a keratin 14 mutation in epidermolysis bullosa simplex--increased severity of disease in a homozygote.</article-title>
                <source>J Invest Dermatol</source>
                <volume>109</volume>
                <fpage>360</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">9284105</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.indelman.2005.272">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Indelman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergman</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sprecher</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>A novel recessive missense mutation in KRT14 reveals striking phenotypic heterogeneity in epidermolysis bullosa simplex.</article-title>
                <source>J Invest Dermatol</source>
                <volume>124</volume>
                <fpage>272</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">15654986</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.irvine.2003.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Irvine</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McLean</surname>
                    <given-names>WH</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>The molecular genetics of the genodermatoses: progress to date and future directions.</article-title>
                <source>Br J Dermatol</source>
                <volume>148</volume>
                <fpage>1</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">12534588</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.jonkman.2005.653">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jonkman</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pasmooij</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pasmans</surname>
                    <given-names>SG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Berg</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ter Horst</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Timmer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pas</surname>
                    <given-names>HH</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Loss of desmoplakin tail causes lethal acantholytic epidermolysis bullosa.</article-title>
                <source>Am J Hum Genet.</source>
                <volume>77</volume>
                <fpage>653</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">16175511</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.kossharnes.2002.87">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Koss-Harnes</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoyheim</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anton-Lamprecht</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gjesti</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jorgensen</surname>
                    <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jahnsen</surname>
                    <given-names>FL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olaisen</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wiche</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gedde-Dahl</surname>
                    <given-names>T</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>A site-specific plectin mutation causes dominant epidermolysis bullosa simplex Ogna: two identical de novo mutations.</article-title>
                <source>J Invest Dermatol</source>
                <volume>118</volume>
                <fpage>87</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">11851880</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.kossharnes.2004.124">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Koss-Harnes</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoyheim</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jonkman</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Groot</surname>
                    <given-names>WP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Weerdt</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nikolic</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wiche</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gedde-Dahl</surname>
                    <given-names>T</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Life-long course and molecular characterization of the original Dutch family with epidermolysis bullosa simplex with muscular dystrophy due to a homozygous novel plectin point mutation.</article-title>
                <source>Acta Derm Venereol</source>
                <volume>84</volume>
                <fpage>124</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">15206692</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.liao.2007.298">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Liao</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhao</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baty</surname>
                    <given-names>DU</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McGrath</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mellerio</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McLean</surname>
                    <given-names>WH</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>A heterozygous frameshift mutation in the V1 domain of keratin 5 in a family with Dowling-Degos disease.</article-title>
                <source>J Invest Dermatol</source>
                <volume>127</volume>
                <fpage>298</fpage>
                <lpage>300</lpage>
                <pub-id pub-id-type="pmid">16917491</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.liu.2012.742">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dopping-Hepenstal</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lovell</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michael</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horn</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fong</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lai-Cheong</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mellerio</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parsons</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McGrath</surname>
                    <given-names>JA</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Autosomal recessive epidermolysis bullosa simplex due to loss of BPAG1-e expression.</article-title>
                <source>J Invest Dermatol.</source>
                <volume>132</volume>
                <fpage>742</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">22113475</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.lugassy.2006.724">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lugassy</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Itin</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ishida-Yamamoto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holland</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huson</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Geiger</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hennies</surname>
                    <given-names>HC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Indelman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bercovich</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uitto</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergman</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McGrath</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richard</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sprecher</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Naegeli-Franceschetti-Jadassohn syndrome and dermatopathia pigmentosa reticularis: two allelic ectodermal dysplasias caused by dominant mutations in KRT14.</article-title>
                <source>Am J Hum Genet</source>
                <volume>79</volume>
                <fpage>724</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">16960809</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.lugassy.2008.1517">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lugassy</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McGrath</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Itin</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shemer</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verbov</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murphy</surname>
                    <given-names>HR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ishida-Yamamoto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Digiovanna</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bercovich</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karin</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vitenshtein</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uitto</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergman</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richard</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sprecher</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>KRT14 haploinsufficiency results in increased susceptibility of keratinocytes to TNF-alpha-induced apoptosis and causes Naegeli-Franceschetti-Jadassohn syndrome.</article-title>
                <source>J Invest Dermatol.</source>
                <volume>128</volume>
                <fpage>1517</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">18049449</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.mcgrath.2012.1115">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McGrath</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stone</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Begum</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simpson</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dopping-Hepenstal</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McMillan</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>South</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pourreyron</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McLean</surname>
                    <given-names>WH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martinez</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mellerio</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parsons</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Germline Mutation in EXPH5 implicates the Rab27B effector protein slac2-b in inherited skin fragility.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2012</year>
                <volume>91</volume>
                <fpage>1115</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">23176819</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.mcgrath.2010.125">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McGrath</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mellerio</surname>
                    <given-names>JE</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Ectodermal dysplasia-skin fragility syndrome.</article-title>
                <source>Dermatol Clin.</source>
                <volume>28</volume>
                <fpage>125</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">19945625</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.moog.1999.376">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Moog</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Die-Smulders</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scheffer</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Vlies</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henquet</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jonkman</surname>
                    <given-names>MF</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Epidermolysis bullosa simplex with mottled pigmentation: clinical aspects and confirmation of the P24L mutation in the KRT5 gene in further patients.</article-title>
                <source>Am J Med Genet</source>
                <volume>86</volume>
                <fpage>376</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">10494094</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.m_ller.2006.719">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>M&#x000fc;ller</surname>
                    <given-names>FB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>K&#x000fc;ster</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wodecki</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Almeida</surname>
                    <given-names>H</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Bruckner-Tuderman</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krieg</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korge</surname>
                    <given-names>BP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arin</surname>
                    <given-names>MJ</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Novel and recurrent mutations in keratin KRT5 and KRT14 genes in epidermolysis bullosa simplex: implications for disease phenotype and keratin filament assembly.</article-title>
                <source>Hum Mutat</source>
                <volume>27</volume>
                <fpage>719</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">16786515</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.nagaowatanabe.2004.236">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nagao-Watanabe</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fukao</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsui</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaneko</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inoue</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawamoto</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kasahara</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nagai</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ichiki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kitajima</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kondo</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Identification of somatic and germline mosaicism for a keratin 5 mutation in epidermolysis bullosa simplex in a family of which the proband was previously regarded as a sporadic case.</article-title>
                <source>Clin Genet</source>
                <volume>66</volume>
                <fpage>236</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15324323</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.nakamura.2005.28">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nakamura</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sawamura</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goto</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakamura</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McMillan</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Park</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kono</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hasegawa</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paku</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakamura</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ogiso</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimizu</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Epidermolysis bullosa simplex associated with pyloric atresia is a novel clinical subtype caused by mutations in the plectin gene (PLEC1).</article-title>
                <source>J Mol Diagn</source>
                <volume>7</volume>
                <fpage>28</fpage>
                <lpage>35</lpage>
                <pub-id pub-id-type="pmid">15681471</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.neufeldkaiser.1997.251">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Neufeld-Kaiser</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sybert</surname>
                    <given-names>VP</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Is cyproheptadine effective in the treatment of subjects with epidermolysis bullosa simplex-Dowling-Meara?</article-title>
                <source>Arch Dermatol</source>
                <volume>133</volume>
                <fpage>251</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">9041851</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.ostrowski.2010.19">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ostrowski</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carmo</surname>
                    <given-names>NB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krumeich</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fanget</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raposo</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Savina</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moita</surname>
                    <given-names>CF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schauer</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hume</surname>
                    <given-names>AN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Freitas</surname>
                    <given-names>RP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goud</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benaroch</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hacohen</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fukuda</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desnos</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seabra</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Darchen</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amigorena</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moita</surname>
                    <given-names>LF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thery</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Rab27a and Rab27b control different steps of the exosome secretion pathway.</article-title>
                <source>Nat Cell Biol.</source>
                <year>2010</year>
                <volume>12</volume>
                <fpage>19</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">19966785</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.pascucci.2006.620">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pascucci</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Posteraro</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pedicelli</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Provini</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Auricchio</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paradisi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castiglia</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Epidermolysis bullosa simplex with mottled pigmentation due to de novo P25L mutation in keratin 5 in an Italian patient.</article-title>
                <source>Eur J Dermatol</source>
                <volume>16</volume>
                <fpage>620</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">17229601</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.pfendner.2005a.241">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pfendner</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouan</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uitto</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2005a</year>
                <article-title>Progress in epidermolysis bullosa: the phenotypic spectrum of plectin mutations.</article-title>
                <source>Exp Dermatol</source>
                <volume>14</volume>
                <fpage>241</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15810881</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.pfendner.2005.111">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pfendner</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uitto</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Plectin gene mutations can cause epidermolysis bullosa with pyloric atresia.</article-title>
                <source>J Invest Dermatol</source>
                <volume>124</volume>
                <fpage>111</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">15654962</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.pfendner.2005b.239">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pfendner</surname>
                    <given-names>EG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sadowski</surname>
                    <given-names>SG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uitto</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2005b</year>
                <article-title>Epidermolysis bullosa simplex: recurrent and de novo mutations in the KRT5 and KRT14 genes, phenotype/genotype correlations, and implications for genetic counseling and prenatal diagnosis.</article-title>
                <source>J Invest Dermatol</source>
                <volume>125</volume>
                <fpage>239</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">16098032</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.rugg.2007.574">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rugg</surname>
                    <given-names>EL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horn</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hill</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Magee</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shemanko</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baty</surname>
                    <given-names>DU</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tidman</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lane</surname>
                    <given-names>EB</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Epidermolysis bullosa simplex in Scotland caused by a spectrum of keratin mutations.</article-title>
                <source>J Invest Dermatol</source>
                <volume>127</volume>
                <fpage>574</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">17039244</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.rugg.2004.4">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rugg</surname>
                    <given-names>EL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leigh</surname>
                    <given-names>IM</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>The keratins and their disorders.</article-title>
                <source>Am J Med Genet C Semin Med Genet</source>
                <volume>131C</volume>
                <fpage>4</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">15452838</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.schara.2004.218">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schara</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tucke</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mortier</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nusslein</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouan</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pfendner</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zillikens</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruckner-Tuderman</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uitto</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wiche</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schroder</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Severe mucous membrane involvement in epidermolysis bullosa simplex with muscular dystrophy due to a novel plectin gene mutation.</article-title>
                <source>Eur J Pediatr</source>
                <volume>163</volume>
                <fpage>218</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">14963703</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.shimizu.1999.950">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shimizu</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takizawa</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pulkkinen</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murata</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawai</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hachisuka</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Udono</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uitto</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishikawa</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Epidermolysis bullosa simplex associated with muscular dystrophy: phenotype-genotype correlations and review of the literature.</article-title>
                <source>J Am Acad Dermatol</source>
                <volume>41</volume>
                <fpage>950</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">10570379</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.shurman.2006.132">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shurman</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Losi-Sasaki</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grimwood</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kivirikko</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tichy</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uitto</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richard</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Epidermolysis Bullosa Simplex with mottled pigmentation: mutation analysis in the first reported Hispanic pedigree with the largest single generation of affected individuals to date.</article-title>
                <source>Eur J Dermatol</source>
                <volume>16</volume>
                <fpage>132</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">16581562</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.smith.1996.450">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eady</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leigh</surname>
                    <given-names>IM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McMillan</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rugg</surname>
                    <given-names>EL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelsell</surname>
                    <given-names>DP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bryant</surname>
                    <given-names>SP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spurr</surname>
                    <given-names>NK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Geddes</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kirtschig</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milana</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Bono</surname>
                    <given-names>AG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Owaribe</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wiche</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pulkkinen</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uitto</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McLean</surname>
                    <given-names>WH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lane</surname>
                    <given-names>EB</given-names>
                  </name>
                </person-group>
                <year>1996</year>
                <article-title>Plectin deficiency results in muscular dystrophy with epidermolysis bullosa.</article-title>
                <source>Nat Genet</source>
                <volume>13</volume>
                <fpage>450</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">8696340</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.smith.2004a.73">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morley</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McLean</surname>
                    <given-names>WH</given-names>
                  </name>
                </person-group>
                <year>2004a</year>
                <article-title>Novel mechanism of revertant mosaicism in Dowling-Meara epidermolysis bullosa simplex.</article-title>
                <source>J Invest Dermatol</source>
                <volume>122</volume>
                <fpage>73</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">14962092</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.smith.2004b.1043">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steinert</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parry</surname>
                    <given-names>DA</given-names>
                  </name>
                </person-group>
                <year>2004b</year>
                <article-title>Modeling effects of mutations in coiled-coil structures: case study using epidermolysis bullosa simplex mutations in segment 1a of K5/K14 intermediate filaments.</article-title>
                <source>Proteins</source>
                <volume>55</volume>
                <fpage>1043</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">15146501</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.s_rensen.2003.472">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>S&#x000f8;rensen</surname>
                    <given-names>CB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andresen</surname>
                    <given-names>BS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jensen</surname>
                    <given-names>UB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jensen</surname>
                    <given-names>TG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jensen</surname>
                    <given-names>PK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gregersen</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bolund</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <article-title>Functional testing of keratin 14 mutant proteins associated with the three major subtypes of epidermolysis bullosa simplex.</article-title>
                <source>Exp Dermatol.</source>
                <year>2003</year>
                <volume>12</volume>
                <fpage>472</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12930305</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.sprecher.2007.572">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sprecher</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Indelman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Khamaysi</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lugassy</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petronius</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergman</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Galli-Galli disease is an acantholytic variant of Dowling-Degos disease.</article-title>
                <source>Br J Dermatol</source>
                <volume>156</volume>
                <fpage>572</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">17300252</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.stephens.1995.577">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stephens</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zlotogorskj</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ehrilich</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wijsman</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Livingston</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sybert</surname>
                    <given-names>V</given-names>
                  </name>
                </person-group>
                <year>1995</year>
                <article-title>Epidermolysis bullosn simplex: a keratin 5 mution is a fully dominant allele in epidermal cytoskcleron function.</article-title>
                <source>Am J Hum Genet</source>
                <volume>56</volume>
                <fpage>577</fpage>
                <lpage>585</lpage>
                <pub-id pub-id-type="pmid">7534039</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.stephens.1997.349">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stephens</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ehrlich</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weaver</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Le</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spencer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sybert</surname>
                    <given-names>VP</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Primers for exon-specific amplification of the KRT5 gene: identification of novel and recurrent mutations in epidermolysis bullosa simplex patients.</article-title>
                <source>J Invest Dermatol</source>
                <volume>108</volume>
                <fpage>349</fpage>
                <lpage>53</lpage>
                <pub-id pub-id-type="pmid">9036937</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.swartling.2010.1072">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Swartling</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karlqvist</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hymnelius</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weis</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vahlquist</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Botulinum toxin in the treatment of sweat-worsened foot problems in patients with epidermolysis bullosa simplex and pachyonychia congenita.</article-title>
                <source>Br J Dermatol.</source>
                <volume>163</volume>
                <fpage>1072</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">20618323</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.szczecinska.2014.1206">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Szczecinska</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nesteruk</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wertheim-Tysarowska</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greenblatt</surname>
                    <given-names>DT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baty</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Browne</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozoemena</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Terron-Kwiatkowski</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McGrath</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mellerio</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morton</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wo&#x0017a;niak</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kowalewski</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Has</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moss</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>Under-recognition of acral peeling skin syndrome: 59 new cases with 15 novel mutations.</article-title>
                <source>Br J Dermatol.</source>
                <volume>171</volume>
                <fpage>1206</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">24628291</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.turcan.2016.1137">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Turcan</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pasmooij</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van den Akker</surname>
                    <given-names>PC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lemmink</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sinke</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jonkman</surname>
                    <given-names>MF</given-names>
                  </name>
                </person-group>
                <article-title>Association of epidermolysis bullosa simplex with mottled pigmentation and EXPH5 mutations.</article-title>
                <source>JAMA Dermatol.</source>
                <year>2016</year>
                <volume>152</volume>
                <fpage>1137</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">27384765</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.weiner.2004.613">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Weiner</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stein</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cash</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Leoz</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fine</surname>
                    <given-names>JD</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Tetracycline and epidermolysis bullosa simplex: a double-blind, placebo-controlled, crossover randomized clinical trial.</article-title>
                <source>Br J Dermatol</source>
                <volume>150</volume>
                <fpage>613</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">15030362</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.werner.2004.990">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Werner</surname>
                    <given-names>NS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Windoffer</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strnad</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grund</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leube</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Magin</surname>
                    <given-names>TM</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Epidermolysis bullosa simplex-type mutations alter the dynamics of the keratin cytoskeleton and reveal a contribution of actin to the transport of keratin subunits.</article-title>
                <source>Mol Biol Cell</source>
                <volume>15</volume>
                <fpage>990</fpage>
                <lpage>1002</lpage>
                <pub-id pub-id-type="pmid">14668478</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.yasukawa.2006.313">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yasukawa</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sawamura</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goto</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakamura</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jung</surname>
                    <given-names>SY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimizu</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Epidermolysis bullosa simplex in Japanese and Korean patients: genetic studies in 19 cases.</article-title>
                <source>Br J Dermatol</source>
                <volume>155</volume>
                <fpage>313</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16882168</pub-id>
              </element-citation>
            </ref>
            <ref id="ebs.REF.yiasemides.2006.387">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yiasemides</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walton</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marr</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Villanueva</surname>
                    <given-names>EV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murrell</surname>
                    <given-names>DF</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>A comparative study between transmission electron microscopy and immunofluorescence mapping in the diagnosis of epidermolysis bullosa.</article-title>
                <source>Am J Dermatopathol</source>
                <volume>28</volume>
                <fpage>387</fpage>
                <lpage>94</lpage>
                <pub-id pub-id-type="pmid">17012912</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="ebs.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="ebs.Suggested_Reading.reflist0">
            <ref id="ebs.REF.van_coster">
              <mixed-citation publication-type="book">Van Coster R, Pulkkinen L. Epidermolysis bullosa: The disease of the cutaneous basement membrane zone. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, eds. <italic toggle="yes">The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID)</italic>. New York, NY: McGraw-Hill. Chap 222. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ommbid.mhmedical.com/">online</ext-link>.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="ebs.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="ebs.Author_History">
          <title>Author History</title>
          <p>Anna L Bruckner, MD (2008-present)Anne W Lucky, MD; Cincinnati Children&#x02019;s Hospital (2005-2008)Ellen G Pfendner, PhD (2005-present)Karen Stephens, PhD; University of Washington, Seattle (1998-2005)Virginia P Sybert, MD; University of Washington, Seattle (1998-2005)</p>
        </sec>
        <sec id="ebs.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>13 October 2016 (ma) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>1 September 2011 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>11 August 2008 (et) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>3 November 2005 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>16 July 2003 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>2 February 2001 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>7 October 1998 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>13 February 1998 (vs) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
